col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


592 Results       Page 1

 [1] 
BMJ: Annals of the Rheumatic Diseases
  original article Date Title Authors   All Authors
1 [GO] 2022―Apr―13 BNT162b2 mRNA COVID-19 vaccine and booster in patients with autoimmune rheumatic diseases: a national cohort study Amir Bieber, Iftach Sagy, Lena Novack, Shay Brikman, Ran Abuhasira, Snait Ayalon, et al. (+3)
2 [GO] 2022―Apr―13 Humoral immune-response to a SARS-CoV-2-BNT162b2 booster in inflammatory arthritis patients who received an inactivated virus vaccine Josefina Durán, Paula Isabel Burgos, Nicole Le Corre, Cinthya Ruiz Tagle, Constanza Martinez-Valdebenito, Mauricio Castro, et al. (+3)
3 [GO] 2022―Apr―08 Severely impaired humoral response against SARS-CoV-2 variants of concern following two doses of BNT162b2 vaccine in patients with systemic lupus erythematosus (SLE) Arthur Mageau, Valentine Marie Ferré, Tiphaine Goulenok, Charlotte Charpentier, Nicole Delory, Chrystel Francois, et al. (+4)
4 [GO] 2022―Apr―07 In the shadow of antibodies: how T cells defend against COVID-19 David S Pisetsky, Kevin L Winthrop
5 [GO] 2022―Mar―25 Outcomes of SARS-CoV-2 infection among children and young people with pre-existing rheumatic and musculoskeletal diseases Lianne Kearsley-Fleet, Min-Lee Chang, Saskia Lawson-Tovey, Ruth Costello, Šárka Fingerhutová, Natálie Švestková, et al. (+19)
6 [GO] 2022―Mar―18 Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study Peter Mandl, Selma Tobudic, Helmut Haslacher, Thomas Karonitsch, Daniel Mrak, Thomas Nothnagl, et al. (+9)
7 [GO] 2022―Mar―14 Pausing methotrexate improves immunogenicity of COVID-19 vaccination in elderly patients with rheumatic diseases Amanthi Nadira Arumahandi de Silva, Leonie Maria Frommert, Fredrik N Albach, Jens Klotsche, Veronika Scholz, Lara Maria Jeworowski, et al. (+7)
8 [GO] 2022―Mar―11 Colchicine prophylaxis is associated with fewer gout flares after COVID-19 vaccination Jie Lu, Yuwei He, Robert Terkeltaub, Mingshu Sun, Zijing Ran, Xinmiao Xu, et al. (+10)
9 [GO] 2022―Mar―11 Increment of immunogenicity after third dose of a homologous inactivated SARS-CoV-2 vaccine in a large population of patients with autoimmune rheumatic diseases Nádia Emi Aikawa, Leonard de Vinci Kanda Kupa, Ana Cristina Medeiros-Ribeiro, Carla Goncalves Schahin Saad, Emily Figueiredo Neves Yuki, Sandra Gofinet Pasoto, et al. (+24)
10 [GO] 2022―Feb―23 Efficacy of COVID-19 vaccines in patients taking immunosuppressants Chen Shen, Malcolm Risk, Elena Schiopu, Salim S Hayek, Tiankai Xie, Lynn Holevinski, et al. (+3)
11 [GO] 2022―Feb―23 EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update Robert B M Landewé, Féline P B Kroon, Alessia Alunno, Aurélie Najm, Johannes WJ Bijlsma, Gerd-Rüdiger R Burmester, et al. (+22)
12 [GO] 2022―Feb―16 Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance Manuel Francisco Ugarte-Gil, Graciela S Alarcón, Zara Izadi, Ali Duarte-García, Cristina Reátegui-Sokolova, Ann Elaine Clarke, et al. (+52)
13 [GO] 2022―Feb―15 Rheumatoid arthritis disease activity assessed by patient-reported outcomes and flow cytometry before and after an additional dose of COVID-19 vaccine Sara K Tedeschi, Jacklyn Stratton, Jack Elias Ellrodt, Mary Grace Whelan, Keigo Hayashi, Kazuki Yoshida, et al. (+6)
14 [GO] 2022―Feb―10 Neutralisation of circulating SARS-CoV-2 delta and omicron variants by convalescent plasma and SARS-CoV-2 hyperimmune intravenous human immunoglobulins for treatment of COVID-19 Fatema Tuz Zahra, Lorenza Bellusci, Gabrielle Grubbs, Hana Golding, Surender Khurana
15 [GO] 2022―Feb―08 Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort Sakir Ahmed, Pankti Mehta, Aby Paul, S Anu, Somy Cherian, Veena Shenoy, et al. (+4)
16 [GO] 2022―Feb―08 Distinct impact of DMARD combination and monotherapy in immunogenicity of an inactivated SARS-CoV-2 vaccine in rheumatoid arthritis Ana Cristina Medeiros-Ribeiro, Karina Rossi Bonfiglioli, Diogo Souza Domiciano, Andrea Yukie Shimabuco, Henrique Carriço da Silva, Carla G S Saad, et al. (+12)
17 [GO] 2022―Feb―04 EULAR 2021 updated viewpoints on SARS-CoV-2 vaccination in patients with RMDs: a guidance to answer patients’ questions Johannes WJ Bijlsma
18 [GO] 2022―Jan―27 Has the gout epidemic peaked in the UK? A nationwide cohort study using data from the Clinical Practice Research Datalink, from 1997 to across the COVID-19 pandemic in 2021 Abhishek Abhishek, Laila J Tata, Mamas Mamas, Anthony J Avery
19 [GO] 2022―Jan―17 Attenuated response to fourth dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series Mayan Teles, Caoilfhionn M Connolly, Sarah Frey, Teresa Po-Yu Chiang, Jennifer J Alejo, Brian J Boyarsky, et al. (+6)
20 [GO] 2022―Jan―13 Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial Michael Bonelli, Daniel Mrak, Selma Tobudic, Daniela Sieghart, Maximilian Koblischke, Peter Mandl, et al. (+18)
21 [GO] 2022―Jan―10 Third COVID-19 vaccine dose with BNT162b2 in patients with ANCA-associated vasculitis Claudius Speer, Maximilian Töllner, Louise Benning, Katrin Klein, Marie Bartenschlager, Christian Nusshag, et al. (+9)
22 [GO] 2021―Dec―31 Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry Pedro M Machado, Saskia Lawson-Tovey, Anja Strangfeld, Elsa F Mateus, Kimme L Hyrich, Laure Gossec, et al. (+25)
23 [GO] 2021―Dec―10 Survival after COVID-19-associated organ failure among inpatients with systemic lupus erythematosus in France: a nationwide study Arthur Mageau, Thomas Papo, Stephane Ruckly, Andrey Strukov, Damien van Gysel, Karim Sacre, Jean-François Timsit
24 [GO] 2021―Dec―07 Risk and prognosis of SARS-CoV-2 infection and vaccination against SARS-CoV-2 in rheumatic and musculoskeletal diseases: a systematic literature review to inform EULAR recommendations Féline P B Kroon, Aurélie Najm, Alessia Alunno, Jan W Schoones, Robert B M Landewé, Pedro M Machado, Victoria Navarro-Compán
25 [GO] 2021―Nov―29 Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors Dimitra Dimopoulou, George Vartzelis, Foteini Dasoula, Maria Tsolia, Despoina Maritsi
26 [GO] 2021―Nov―29 Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis Elisabeth Simader, Selma Tobudic, Peter Mandl, Helmuth Haslacher, Thomas Perkmann, Thomas Nothnagl, et al. (+8)
27 [GO] 2021―Nov―26 Spectrum of short-term inflammatory musculoskeletal manifestations after COVID-19 vaccine administration: a report of 66 cases Francesco Ursini, Piero Ruscitti, Vincenzo Raimondo, Rossella De Angelis, Fabio Cacciapaglia, Erika Pigatto, et al. (+27)
28 [GO] 2021―Nov―25 Safety and disease flare of autoimmune inflammatory rheumatic diseases: a large real-world survey on inactivated COVID-19 vaccines Yong Fan, Yan Geng, Yu Wang, Xuerong Deng, Guangtao Li, Juan Zhao, et al. (+10)
29 [GO] 2021―Nov―24 Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2 Marcella Visentini, Laura Gragnani, Stefano Angelo Santini, Teresa Urraro, Annalisa Villa, Monica Monti, et al. (+12)
30 [GO] 2021―Nov―24 Efficacy and safety of SARS-CoV-2 revaccination in non-responders with immune-mediated inflammatory disease David Simon, Koray Tascilar, Filippo Fagni, Katja Schmidt, Gerhard Krönke, Arnd Kleyer, et al. (+8)
31 [GO] 2021―Nov―22 Response to: Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients’ by Trahtemberg et al Marvin J Fritzler, Uriel Trahtemberg
32 [GO] 2021―Nov―22 Influenza outcomes in patients with inflammatory joint diseases and DMARDs: how do they compare to those of COVID-19? Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Johan Askling
33 [GO] 2021―Nov―22 Correspondence on ‘Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients’ by Trahtemberg et al Yudong Liu
34 [GO] 2021―Nov―10 Better outcomes of COVID-19 in vaccinated compared to unvaccinated patients with systemic rheumatic diseases Charalampos Papagoras, George E Fragoulis, Nikoleta Zioga, Theodora Simopoulou, Kleopatra Deftereou, Eleni Kalavri, et al. (+25)
35 [GO] 2021―Oct―10 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 Alessia Alunno, Aurélie Najm, Pedro M Machado, Heidi Bertheussen, Gerd-Rüdiger R Burmester, Francesco Carubbi, et al. (+18)
36 [GO] 2021―Oct―05 BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus Quentin Moyon, Delphine Sterlin, Makoto Miyara, François Anna, Alexis Mathian, Raphael Lhote, et al. (+13)
37 [GO] 2021―Sep―23 B-cell targeted therapy is associated with severe COVID-19 among patients with inflammatory arthritides: a 1-year multicentre study in 1116 successive patients receiving intravenous biologics Renaud Felten, Pierre-Marie Duret, Elodie Bauer, Nathanael Sedmak, Julien H Djossou, Massiva Bensalem, et al. (+23)
38 [GO] 2021―Sep―23 Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series Caoilfhionn M Connolly, Teresa Po-Yu Chiang, Brian J Boyarsky, Jake A Ruddy, Mayan Teles, Jennifer L Alejo, et al. (+7)
39 [GO] 2021―Sep―13 SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future Kevin L Winthrop, Richard J Whitley, Daniel Aletaha
40 [GO] 2021―Sep―07 Booster-dose SARS-CoV-2 vaccination in patients with autoimmune disease: a case series Caoilfhionn M Connolly, Mayan Teles, Sarah Frey, Brian J Boyarsky, Jennifer L Alejo, William A Werbel, et al. (+5)
41 [GO] 2021―Sep―06 Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases Claire Cook, Naomi J Patel, Kristin M. D’Silva, Tiffany Y -T Hsu, Michael DiIorio, Lauren Prisco, et al. (+6)
42 [GO] 2021―Sep―06 SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases Saskia Lawson-Tovey, Kimme L Hyrich, Laure Gossec, Anja Strangfeld, Loreto Carmona, Bernd Raffeiner, et al. (+8)
43 [GO] 2021―Aug―24 Antibody response to the Janssen/Johnson & Johnson SARS-CoV-2 vaccine in patients with rheumatic and musculoskeletal diseases Teresa Po-Yu Chiang, Caoilfhionn M Connolly, Jake A Ruddy, Brian J Boyarsky, Jennifer L Alejo, William A Werbel, et al. (+5)
44 [GO] 2021―Aug―23 Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry” by Sparks et al Elisa Gremese, Gianfranco Ferraccioli
45 [GO] 2021―Aug―23 Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by Sparks et al Zachary S Wallace, Jeffrey A Sparks, Philip C Robinson, Pedro M Machado, Jinoos Yazdany
46 [GO] 2021―Aug―13 Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry” by Sparks et al Ronald F van Vollenhoven, Sander W Tas, Michael T Nurmohamed
47 [GO] 2021―Aug―13 Response to: Correspondence on “Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis” by Sparks et al Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Philip C Robinson, Pedro M Machado, Jinoos Yazdany
48 [GO] 2021―Aug―06 Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression Maria Prendecki, Candice Clarke, Helena Edwards, Stacey McIntyre, Paige Mortimer, Sarah Gleeson, et al. (+10)
49 [GO] 2021―Aug―02 Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: one swallow does not make a summer Pier Luigi Meroni, Maria Orietta Borghi
50 [GO] 2021―Jul―20 Immunotherapies and COVID-19 mortality: a multidisciplinary open data analysis based on FDA’s Adverse Event Reporting System Maximilian Pistor, Andreas G F Hoepner, Yanan Lin, Simon Jung, Claudio L Bassetti, Andrew Chan, et al. (+2)
51 [GO] 2021―Jul―20 SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity Daniel Mrak, Selma Tobudic, Maximilian Koblischke, Marianne Graninger, Helga Radner, Daniela Sieghart, et al. (+12)
52 [GO] 2021―Jul―16 Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report Basil Golding, Youri Lee, Hana Golding, Surender Khurana
53 [GO] 2021―Jul―02 Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey’ Fernando Montero, Isabel Castrejón, Julia Martínez-Barrio, Juan Carlos Nieto-González, Javier Rivera, José María Álvaro-Gracia, Juan Molina Collada
54 [GO] 2021―Jul―02 Response to ‘Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’’ by Montero et al Alessandro Tomelleri, Lorenzo Dagna, Corrado Campochiaro
55 [GO] 2021―Jun―29 Unexpected impact of COVID-19 lockdown on spinal mobility and health perception in spondyloarthritis Sophie De Mits, Ann-Sophie De Craemer, Liselotte Deroo, Thomas Renson, Filip E Van den Bosch, Philippe Carron, Dirk Elewaut
56 [GO] 2021―Jun―25 Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis Serena Bugatti, Ludovico De Stefano, Silvia Balduzzi, Maria Immacolata Greco, Terenzj Luvaro, Irene Cassaniti, et al. (+9)
57 [GO] 2021―Jun―23 Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study’’ by Klopfenstein et al Robert BM Landewé, Sofia Ramiro, Rémy L M Mostard
58 [GO] 2021―Jun―23 Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ Timothée Klopfenstein, Vincent Gendrin, Thierry Conrozier, Aurélie Gerazime, Marc Puyraveau, Souheil Zayet
59 [GO] 2021―Jun―22 Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City Medha Barbhaiya, Jonah M. Levine, Vivian P. Bykerk, Deanna Jannat-Khah, Lisa A. Mandl
60 [GO] 2021―Jun―18 Disease activity and humoral response in patients with inflammatory rheumatic diseases after two doses of the Pfizer mRNA vaccine against SARS-CoV-2 Yolanda Braun-Moscovici, Marielle Kaplan, Maya Braun, Doron Markovits, Samy Giryes, Kohava Toledano, et al. (+3)
61 [GO] 2021―Jun―14 Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study Victoria Furer, Tali Eviatar, Devy Zisman, Hagit Peleg, Daphna Paran, David Levartovsky, et al. (+23)
62 [GO] 2021―Jun―07 Use of Janus kinase inhibitors in COVID-19: a prospective observational series in 522 individuals Oleg Melikhov, Tatiana Kruglova, Karine Lytkina, Georgy Melkonyan, Elena Prokhorovich, Gleb Putsman, et al. (+4)
63 [GO] 2021―May―28 Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry Jeffrey A Sparks, Zachary S Wallace, Andrea M Seet, Milena A Gianfrancesco, Zara Izadi, Kimme L Hyrich, et al. (+58)
64 [GO] 2021―May―28 SARS-COV-2 vaccination after stem cell transplantation for scleroderma Doron Rimar, Gleb slobodin, Alona Paz, Israel Henig, Tsila Zuckerman
65 [GO] 2021―May―26 POS1464-HPR ASSESSMENT OF EMOTIONAL WELL-BEING IN RHEUMATIC PATIENTS DURING COVID-19 LOCKDOWN THROUGH A WEB-BASED SURVEY APPROACH C. Iannuccelli, B. Lucchino, C. Gioia, A. Gattamelata, F. Giardina, M. DI Franco, et al. (+2)
66 [GO] 2021―May―26 POS1468-HPR THE IMPACT OF COVID-19 ON RHEUMATOLOGY HEALTH CARE WORKERS AND THEIR SCIENTIFIC OUTPUT: HEAVY LIES THE CROWN ON FEMALE RHEUMATOLOGISTS C. Kirchler, M. R. Andrews, E. Mosor, K. Thaler, T. Stamm, R. Fritsch-Stork, C. Duftner
67 [GO] 2021―May―26 AB0690 HOW DID COVID-19 AFFECT PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES TREATED WITH DMARDs - EXPERIENCE FROM A ROMANIAN RHEUMATOLOGY HOSPITAL A. Trandafir, I. Saulescu, A. Balanescu, D. Opris-Belinski, V. Bojinca, F. Berghea, et al. (+10)
68 [GO] 2021―May―26 POS1466-HPR IMPACT OF COVID-19 PANDEMIC ON ADHERENCE BEHAVIOR OF LATIN-AMERICAN PATIENTS WITH RHEUMATIC DISEASES I. A. Moreno-Arquieta, G. G. Sánchez Mendieta, D. E. Flores Alvarado, J. A. Esquivel Valerio, D. Á. Galarza-Delgado
69 [GO] 2021―May―26 POS1463-HPR IMPACT OF COVID-19 PANDEMIC ON DISEASE ACTIVITY AND EMOTIONAL WELL-BEING AMONG RHEUMATOID ARTHRITIS PATIENTS: A TELEMEDICINE STUDY B. Lucchino, C. Iannuccelli, C. Gioia, G. Dolcini, M. DI Franco
70 [GO] 2021―May―26 AB0668 THE ONSET OF RHEUMATOID ARTHRITIS AFTER COVID-19 - COINCIDENCE OR CONNECTED? V. Derksen, T. Kissel, F. Lamers-Karnebeek, A. Van der Bijl, A. C. Venhuizen, T. Huizinga, et al. (+3)
71 [GO] 2021―May―26 AB0702 PITFALLS IN THE DIAGNOSIS OF COVID-19 - EXPERIENCES FROM A RHEUMATOLOGY OUTPATIENT CLINIC S. G. Werner, H. E. Langer, P. Höhenrieder, R. Chatelain
72 [GO] 2021―May―26 Methotrexate hampers immunogenicity to BNT162b2 mRNA COVID-19 vaccine in immune-mediated inflammatory disease Rebecca H Haberman, Ramin Herati, David Simon, Marie Samanovic, Rebecca B Blank, Michael Tuen, et al. (+20)
73 [GO] 2021―May―26 AB0694 COVID-19 İNFECTION IN PATIENTS WITH RHEUMATIC DISEASES: TWO CENTERS EXPERIENCE A. Şahin, M. A. Gedikli, M. E. Derin, B. Karakaş, B. Karataş, N. Çabuk Çelik, İ. Yalçin
74 [GO] 2021―May―26 POS1458-HPR DIGITAL RHEUMATOLOGY IN THE ERA OF COVID-19: RESULTS OF A NATIONAL PATIENT AND PHYSICIAN SURVEY A. Kernder, H. Morf, P. Klemm, D. Vossen, M. Meyer, I. Haase, et al. (+7)
75 [GO] 2021―May―26 Broad clinical spectrum of SARS-CoV-2-associated inflammatory joint disease in adults: a report of 35 cases from the COVID-19 & Autoimmune Systemic Disease Italian study group Francesco Ursini, Piero Ruscitti, Salvatore D'Angelo, Fabio Cacciapaglia, Rossella De Angelis, Corrado Campochiaro, et al. (+14)
76 [GO] 2021―May―26 POS1491-HPR MENTAL HEALTH OUTCOMES AMONG HEALTH CARE WORKERS DURING THE CORONAVIRUS-19 PANDEMIC O. Hamdi, M. Sellami, S. Miladi, A. Fazaa, L. Souabni, K. Ouenniche, et al. (+4)
77 [GO] 2021―May―26 POS1422 CORRELATES OF TESTING POSITIVE FOR SARS-COV-2 IN PATIENTS WITH RHEUMATIC AD MUSCULOSKELETAL DISEASES N. Singh, I. Huang, M. Singleton, A. Bays, J. Sabo, S. Chung, et al. (+7)
78 [GO] 2021―May―26 POS1496-HPR IS NUTRITIONAL FOLLOW-UP IN PATIENTS LIVING WITH RHEUMATOID ARTHRITIS BETTER WITH TELECONSULTATION? - EXPERIENCE BEFORE AND AFTER PANDEMIC I. Mozo, M. Marquez, O. Valencia
79 [GO] 2021―May―26 Challenges in the diagnosis of early rheumatoid arthritis in times of COVID-19 Bernardo D'Onofrio, Ludovico De Stefano, Bianca Lucia Palermo, Blerina Xoxi, Antonio Manzo, Carlomaurizio Montecucco, Serena Bugatti
80 [GO] 2021―May―26 AB0673 THE ROUTINE HEALTH CARE OF PATIENTS WITH RHEUMATIC DISEASES DURING THE PANDEMIC OF COVID-19 S. Mariem, M. Yasmine, S. Miladi, A. Fazaa, L. Souebni, K. Ouenniche, et al. (+4)
81 [GO] 2021―May―26 AB0682 RHEUMATOLOGY TEACHING IN TIMES OF COVID-19 Y. Chang, J. Nicholls
82 [GO] 2021―May―26 AB0681 HOW COMMON IS COVID-19 IN CHILDREN, YOUNG PEOPLE AND ADULTS WITH RHEUMATIC DISEASES? RESULTS FROM THE INTERNATIONAL COVID-19 EUROPEAN PATIENT REGISTRY S. Shoop-Worrall, S. Verstappen, W. Costello, S. Angevare, Y. Uziel, C. Wouters, et al. (+2)
83 [GO] 2021―May―26 AB0674 RAPID ADOPTION OF TELEMEDICINE IN RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY S. A. Yeoh, K. Young, M. Putman, E. Graef, F. Berenbaum, R. Conway, et al. (+13)
84 [GO] 2021―May―26 AB0670 THE COURSE AND OUTCOMES OF COVID-19 IN PATIENTS WITH ANCA-ASSOCIATED SYSTEMIC VASCULITIS, RECEIVING ANTI-B CELL THERAPY WITH RITUXIMAB T. Beketova, V. Babak, M. Suprun
85 [GO] 2021―May―26 AB0695 PATTERN OF COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES UNDERGOING BIOLOGICAL THERAPY: A COHORT EXPERIENCE C. Ancuta, C. Pomirleanu, G. Strugariu, L. Petrariu, E. Ancuta, C. Bran, et al. (+2)
86 [GO] 2021―May―26 AB0705 SHORT-TERM OUTCOMES OF COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES WHO ARE TREATED BY BIOLOGICAL AND TARGETED SYNTHETIC DMARDS: OBSERVATIONAL SINGLE-CENTER STUDY E. Luchikhina, D. Karateev, O. Semenova, O. Matveychuk, T. Kuznetsova
87 [GO] 2021―May―26 AB0689 INCIDENCE AND SEVERITY OF COVID-19 IN PATIENTS WITH SPONDYLOARTHRITIS IN ARGENTINA: EXPERIENCE IN A COUNTRY WITH STRICT ISOLATION V. Martire, C. Airoldi, M. S. Gálvez Elkin, M. Machado Escobar, N. Callahuara, V. Duarte, et al. (+22)
88 [GO] 2021―May―26 AB0658 FEAR OF COVID-19 IN POSTPARTUM WOMEN WITH RHEUMATIC DISEASE L. G. Espinosa Banuelos, M. E. Corral Trujillo, C. M. Skinner Taylor, L. Pérez Barbosa, R. A. Rodriguez Chavez, A. Y. Lujano Negrete, et al. (+3)
89 [GO] 2021―May―26 AB0653 COURSE OF COVID-19 INFECTION IN A SERIES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS C. Cetin, N. Aliyeva, Y. Yalçinkaya, A. Gül, M. Inanc, B. Artim-Esen
90 [GO] 2021―May―26 AB0703 THE COURSE OF COVID-19 INFECTION IN PATIENTS WITH ARTHRITIS RECEIVING TARGETED DMARDS E. Koltsova, G. Lukina, E. Shmidt, K. Lytkina, E. Rozochkina, E. Zhilyaev
91 [GO] 2021―May―26 AB0688 SEVERITY OF COVID-19 INFECTION IN RHEUMATIC IMMUNE-MEDIATEDINFLAMMATORY DISEASES. STUDY IN A SINGLE UNIVERSITY HOSPITAL D. Martínez-López, D. Prieto-Peña, L. Sanchez-Bilbao, A. Herrero-Morant, C. Álvarez-Reguera, M. Trigueros-Vazquez, et al. (+2)
92 [GO] 2021―May―26 AB0692 REACTIVE ARTHRITIS ASSOCIATED WITH COVID-19 INFECTION: A REVIEW F. Alkindi, K. Alseiari, K. Al Naqbi
93 [GO] 2021―May―26 AB0667 A PROSPECTIVE STUDY INTO COVID-19 LIKE SYMPTOMS IN PATIENTS WITH AND WITHOUT IMMUNE MEDIATED INFLAMMATORY DISEASES OR IMMUNOMODULATING DRUGS L. van Ouwerkerk, A. Van der Meulen, M. Ninaber, Y. K. O. Teng, T. Huizinga, C. Allaart
94 [GO] 2021―May―26 AB0655 RHEUMATOID ARTHRITIS ACTIVITY BEFORE AND AFTER COVID-19 LOCKDOWN PERIOD M. Jordhani, D. Ruci, F. Skana, E. Memlika
95 [GO] 2021―May―26 AB0872-HPR IMPACT OF COVID-19 ON A PHYSICAL ACTIVITY FEASIBILITY PILOT STUDY: THE PIPPRA EXPERIENCE L. Larkin, A. Moses, S. Gallagher, A. Fraser, B. A. Esbensen, J. Green, et al. (+2)
96 [GO] 2021―May―26 AB0687 EFFECT OF COVID-19 ON PATIENTS ATTENDING AMBULATORY DEEP VENOUS THROMBOSIS OUT-PATIENT CLINIC: A RETROSPECTIVE, COHORT ANALYSIS[KI1] [KI1]101 CHARACTERS T. Hill, K. P. Iyengar, A. Nune
97 [GO] 2021―May―26 AB0685 IMPACT OF COVID-19 ON PATIENTS WITH RHEUMATIC DISEASES: EXPERIENCE OF THE DEPARTMENT OF RHEUMATOLOGY OF THE UNIVERSITY HOSPITAL OF IBN ROCHD OF CASABLANCA H. El Moutaouakil, Z. El Ouali, K. Nassar, S. Janani
98 [GO] 2021―May―26 AB0664 THE PSYCHOLOGICAL STATE OF THE PATIENTS WITH RHEUMATIC DISEASES AND HOSPITAL WORKERS DURING THE CORONAVIRUS DISEASE (COVID-19) OUTBREAK T. Lisitsyna, D. Veltishchev, A. Borisova, E. Nasonov, A. Lila
99 [GO] 2021―May―26 AB0651 CASE-REPORT: ORGANIZING PNEUMONIA IN A PREGNANT WOMAN WITH RHEUMATOID ARTHRITIS DURING COVID-19 PANDEMIC A. Cornillie, C. Grivegnee
100 [GO] 2021―May―26 AB0657 PERCEIVED STRESS AND FOOD INSECURITY IN PREGNANT AND POSTPARTUM WOMEN WITH RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC L. G. Espinosa Banuelos, P. R. Ancer Rodríguez, M. G. Herrera López, C. M. Skinner Taylor, L. Pérez Barbosa, R. Moyeda Martinez, et al. (+4)
101 [GO] 2021―May―26 AB0868-HPR ADHERENCE TO DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN RHEUMATIC DISEASES DURING COVID-19 PANDEMIC I. A. Moreno-Arquieta, G. G. Sánchez Mendieta, D. E. Flores Alvarado, J. A. Esquivel Valerio, D. Á. Galarza-Delgado
102 [GO] 2021―May―26 AB0877-HPR EXERCISE COMPLIANCE AND DISEASE STATUS IN PATIENTS WITH RHEUMATIC DISEASES DURING COVID-19 PANDEMIC G. G. Pala, Z. Tuna, N. G. Tore, S. Bayram, F. Sarİ, M. A. Ozturk, D. Oskay
103 [GO] 2021―May―26 AB0903-HPR DURATION OF TELEPHONE CONSULTATIONS AMONGST RHEUMATOLOGY PRACTITIONERS IN A DISTRICT GENERAL HOSPITAL - ADAPTING TO REMOTE CONSULTATION IN A COVID-19 PANDEMIC L. Parker, F. Coldstream
104 [GO] 2021―May―26 AB0908-HPR SIGNED, SEALED, DELIVERED: PHARMACISTS ACHIEVING BETTER CARE CLOSER TO HOME IN RHEUMATOLOGY HIGH COST DRUG MANAGEMENT DURING THE COVID-19 PANDEMIC S. Gohil
105 [GO] 2021―May―26 AB0920-PARE WHAT WE LEARNED DURING COVID-19 PANDEMIC J. Grygielska
106 [GO] 2021―May―26 AB0677 GENDER DIFFERENCES ON THE IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1) M. Garrido-Cumbrera, H. Marzo-Ortega, L. Christen, L. Carmona, J. Correa-Fernández, S. Sanz-Gómez, et al. (+10)
107 [GO] 2021―May―26 AB0708 HIGH DRUG RETENTION RATES DESPITE B/TSDMARD INTERRUPTIONS IN COVID-19 PANDEMIC CHAOS S. Gulle, Y. Erez, A. Karakas, T. Yüce İnel, S. B. Kocaer, T. Demirci Yildirim, et al. (+4)
108 [GO] 2021―May―26 AB0907-HPR UNEXPECTED DIFFERENCE IN ACCEPTANCE OF TELECONSULTATION BETWEEN PATIENTS WITH LUPUS AND RHEUMATOID ARTHRITIS WHO UNDERWENT TO A DEVELOPED AND IMPLEMENTED TELEMEDICINE INNOVATIVE PROGRAM AFTER THE DECLARATION OF QUARANTINE DUE TO THE COVID-19 PANDEMIC IN COLOMBIA S. M. Hernández-Zambrano, R. A. Castiblanco-Montañez, J. Chavez-Chavez, D. P. Rivera-Triana, A. Aza, L. Villarreal, et al. (+3)
109 [GO] 2021―May―26 AB0500 IMPACT OF COVID-19 PANDEMIC IN OVERALL HEALTH AND FUNCTIONING IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS: RESULTS FROM THE REUMAVID STUDY (PHASE 1) D. Benavent, M. Garrido-Cumbrera, C. Plasencia, L. Christen, H. Marzo-Ortega, J. Correa-Fernández, et al. (+3)
110 [GO] 2021―May―26 AB0921-PARE PRACTICES AND BEHAVIORS DURING THE COVID-19 PANDEMIC IN PATIENTS WHO PARTIALLY ATTEND TO AN EDUCATIONAL PROGRAM ON RHEUMATOID ARTHRITIS. A CROSS-SECTIONAL SURVEY F. Rodriguez, D. Buitrago-Garcia, G. Sánchez, P. Santos-Moreno
111 [GO] 2021―May―26 AB0669 DEPRESSION AND ANXIETY MIGHT NOT BE INCREASED DURING COVID-19 PANDEMIC IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS E. Erpek, D. Solmaz, D. Bayraktar, G. Duran, G. Kabadayi, E. Durak Ediboglu, et al. (+8)
112 [GO] 2021―May―26 AB0676 FEARS AND HOPES DURING THE COVID-19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1) M. Garrido-Cumbrera, H. Marzo-Ortega, L. Christen, L. Carmona, J. Correa-Fernández, S. Sanz-Gómez, et al. (+10)
113 [GO] 2021―May―26 AB0901-HPR SOCIAL AND PSYCHOLOGICAL IMPACT OF THE CONTAINEMENT DURING COVID-19 PANDEMIC ON PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES T. El Joumani, H. Rkain, T. Fatima Zahrae, H. Kenza, A. Radouan, N. Laila, et al. (+5)
114 [GO] 2021―May―26 AB0675 COUNTRY COMPARISON ON THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1) M. Garrido-Cumbrera, H. Marzo-Ortega, L. Christen, L. Carmona, J. Correa-Fernández, S. Sanz-Gómez, et al. (+10)
115 [GO] 2021―May―26 AB0661 EFFECT OF COVID-19 PANDEMIC ON SLEEP DISORDERS IN PATIENTS WITH INFLAMMATORY ARTHRITIS F. Ingegnoli, M. Buoli, C. Posio, R. DI Taranto, R. Caporali
116 [GO] 2021―May―26 AB0899-HPR THE IMPACT OF CORONAVIRUS (COVID-19) PANDEMIC ON THERAPEUTIC MAINTENANCE IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES T. El Joumani, H. Rkain, T. Fatima Zahrae, H. Kenza, A. Radouan, N. Laila, et al. (+5)
117 [GO] 2021―May―26 AB0665 SWITCHING INTRAVENOUS ABATACEPT AND TOCILIZUMAB TO SUBCUTANEOUS INJECTIONS DURING THE COVID-19 PANDEMIC: A FRENCH EXPERIENCE A. Combier, S. Wanono, L. Poiroux, C. Frantz, E. Descamps, O. Fogel, et al. (+5)
118 [GO] 2021―May―26 AB0910-HPR LEVELS OF DEPRESSION AND ANXIETY DURING COVID-19 PANDEMIC: AT WHAT DEGREE ARE HEALTH CARE WORKERS AFFECTED IN TUNISIA? K. Ben Abdelghani, O. Hamdi, S. Miladi, M. Sellami, K. Ouenniche, L. Souabni, et al. (+4)
119 [GO] 2021―May―26 AB0902-HPR COVID-19 PANDEMIC: KNOWLEDGE, BELIEVES AND FEARS IN PATIENTS WITH CHRONIC INFLAMMATORY RHEUMATIC DISEASES IN A DEVELOPING COUNTRY T. El Joumani, H. Rkain, T. Fatima Zahrae, H. Kenza, A. Radouan, N. Laila, et al. (+5)
120 [GO] 2021―May―26 AB0707 RHEUMATOLOGY PATIENT CARE IN THE COVID-19 PANDEMIC: TELEMEDICINE, DELEGATION, PATIENT SATISFACTION AND VACCINATION BEHAVIOUR T. Thiele, S. Beider, H. Kühl, G. Miehlke, A. Cossmann, A. Holz, et al. (+5)
121 [GO] 2021―May―26 AB0683 OSTEOARTHRITIS PAIN AND COVID-19 PANDEMIC: THE LOCKDOWN IMPACT F. Orsini, O. De Lucia, F. Ingegnoli, G. Cincinelli, G. Armentaro, R. DI Taranto, R. Caporali
122 [GO] 2021―May―26 AB0898-HPR WICH FACTORS ARE RELATED TO PAINFUL EXPERIENCE IN PATIENTS AFFECTED BY CHRONIC INFLAMMATORY RHEUMATIC DISEASE DURING THE COVID-19 PANDEMIC? T. El Joumani, H. Rkain, T. Fatima Zahrae, H. Kenza, R. Abouqal, N. Laila, et al. (+5)
123 [GO] 2021―May―26 AB0696 ANTI-PHOSPHOLIPID AUTOANTIBODIES IN COVID-19 PATIENTS M. Jordhani, D. Ruci, V. Ruci
124 [GO] 2021―May―26 AB0700 TOCILIZUMAB DID NOT REDUCE MORTALITY IN SEVERE COVID-19 PATIENTS BUT CAUSED THROMBOCYTOSIS Z. Öztürk, S. M. Türk, D. Karataş, Ü. Erkorkmaz, K. Özmen Süner, H. Dheir, et al. (+3)
125 [GO] 2021―May―26 AB0679 NAILFOLD VIDEOCAPILLAROSCOPY RESULTS IN COVID-19 PATIENTS RECOVERED FROM DIFFERENT DISEASE SEVERITY E. Gotelli, P. F. Bica, T. Aloe’, A. Sulli, M. Grosso, C. Pizzorni, et al. (+5)
126 [GO] 2021―May―26 AB0697 ANTI-SARS-COV-2 ANTIBODIES AND AUTOANTIBODIES IN COVID-19 PATIENTS SURVIVED AFTER ICU ADMISSION, 6 MONTHS LATER K. Bitzogli, E. Magira, L. Chatzis, E. Jahaj, H. Alexopoulos, M. Dalakas, et al. (+3)
127 [GO] 2021―May―26 AB0706 ASSOCIATED RISK FACTORS AND OUTCOMES IN HOSPITALISED COVID-19 PATIENTS WITH BIOLOGICS AND JAK-INHIBITORS: A REPORT FROM A CENTER SPECIALISED IN IMMUNE-MEDIATED DISEASES A. M. Anzola Alfaro, L. R. Caballero Motta, J. C. Nieto González, L. Menchen Viso, O. Baniandrés, C. Lobo Rodríguez, et al. (+3)
128 [GO] 2021―May―26 AB0710 ANISOCYTOSIS INDEX AS AN EARLY PREDICATOR OF HOSPITAL MORTALITY IN PATIENTS WITH COVID-19 PNEUMONIA FROM A LEVEL III HOSPITAL. LIMA PERU J. Ravelo
129 [GO] 2021―May―26 AB0666 PROGNOSTIC VALUE OF SERUM KREBS VON DEN LUNGEN-6 GLYCOPROTEIN CIRCULATING LEVELS IN COVID-19 PNEUMONIA: A PROSPECTIVE COHORT STUDY D. Lobo Prat, I. Castellví, D. Castillo, S. Orozco, A. Mariscal, L. Martínez-Martínez, et al. (+12)
130 [GO] 2021―May―26 AB0660 COVID-19 SHARES CLINICAL FEATURES WITH ANTI-MELANOMA DIFFERENTIATION ASSOCIATED PROTEIN 5 POSITIVE DERMATOMYOSITIS AND ADULT STILL’S DISEASE Y. Kondo, Y. Kaneko, H. Takei, H. Tamai, T. Takeuchi
131 [GO] 2021―May―26 AB0680 SARCOPENIA RATE IN COVID-19 SURVIVORS D. Levy, M. Giannini, W. Oulehri, M. Riou, C. Marcot, A. Meyer, B. Geny
132 [GO] 2021―May―26 AB0652 FERRITIN IS ASSOCIATED WITH THE SEVERITY OF LUNG INVOLVEMENT BUT NOT WITH WORSE PROGNOSIS IN PATIENTS WITH COVID-19: DATA FROM TWO ITALIAN COVID-19 UNITS F. Carubbi, A. Alunno, L. Salvati, C. Ferri, D. Grassi
133 [GO] 2021―May―26 AB0709 CHARACTERIZATION OF NAILFOLD CAPILLAROSCOPY IN COVID-19: A CASE CONTROL STUDY P. E. Bermudez Bermejo, R. Jimenez-Soto, A. Sanchez Rodríguez, A. Turrent, D. Mercado Velasco, I. Bravo-Lee, et al. (+3)
134 [GO] 2021―May―26 AB0704 TELEMEDICINE AT THE TIME OF COVID-19: THE EXPERIENCE WITH RA PATIENTS TREATED WITH JAK-INHIBITORS C. Garufi, F. R. Spinelli, S. Mancuso, F. Ceccarelli, F. Conti
135 [GO] 2021―May―26 AB0698 CORONAVIRUS 19 DISEASE VACCINE: PERCEPTIONS AND INTENTIONS OF TUNISIAN PATIENTS WITH RHEUMATOID ARTHRITIS K. Ben Abdelghani, H. Boussaa, S. Miladi, M. Sellami, L. Souabni, K. Ouenniche, et al. (+4)
136 [GO] 2021―May―26 AB0693 NON-STEROIDAL ANTI-INFLAMMATORY DRUGS DURING CORONAVIRUS 19 PANDEMIC: WHAT DO TUNISIAN RHEUMATOLOGISTS THINK? H. Ferjani, H. Boussaa, K. Maatallah, H. Khalfalli, D. Kaffel, W. Hamdi
137 [GO] 2021―May―26 AB0386 CORONAVIRUS INFECTION AND VASCULITIS: IDENTIFYING ASSOCIATIONS MINING THE BIOMEDICAL LITERATURE A. Rodriguez-Pla, R. Cartin-Ceba
138 [GO] 2021―May―26 AB0691 ANALYSIS OF SARS-COV-2 ANTIBODIES IN NON-COVID-19 PATIENTS: COMPARISON BETWEEN SYSTEMIC SCLEROSIS PATIENTS AND HEALTHY CONTROLS L. Giardullo, C. Rotondo, A. Corrado, N. Maruotti, R. Colia, A. Altomare, et al. (+3)
139 [GO] 2021―May―26 AB0671 NO EVIDENCE OF SARS-COV-2 IN THE KNEE JOINT: A CADAVER STUDY M. Grassi, V. Giorgi, M. Nebuloni, P. Zerbi, M. R. Gismondo, F. Salaffi, et al. (+3)
140 [GO] 2021―May―26 AB0739 MULTISYSTEM INFLAMMATORY SYNDROME ASSOCIATED WITH SARS-COV-2 INFECTION AND E.COLI SEPSIS: THE POTENTIAL ROLE OF PROCALCITONINE AS A RAPID DIAGNOSTIC BIOMARKER TO DISTINGUISH TWO DIFFERENT PHASES OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME M. Gilio, S. B. Morella, F. Picaro, C. Acierno, D. Palazzo, A. Erezanu, et al. (+3)
141 [GO] 2021―May―26 AB0656 SARS-CoV-2 INFECTION IN PATIENTS WITH RHEUMATIC DISEASE: A TERTIARY SINGLE-CENTER EXPERIENCE A. Halbac, B. Balan, C. Tamas, M. M. Tamas, I. Felea, I. Filipescu, et al. (+4)
142 [GO] 2021―May―26 AB0662 IMPACT OF THE SARS-CoV-2 PANDEMIC IN A POPULATION OF PATIENTS FOLLOWED IN A RHEUMATOLOGY DEPARTMENT S. Lahrichi, K. Nassar, S. Janani
143 [GO] 2021―May―26 AB0663 COMPARING METHODS FOR DETERMINING ANTIBODIES TO SARS-CoV-2 USING A RAPID TEST AND ENZYME-LINKED IMMUNOSORBENT ASSAY G. Gridneva, E. Aronova, S. Glukhova, M. Cherkasova, B. Belov, K. Nurbaeva, E. Salyanova
144 [GO] 2021―May―26 AB0672 PSYCHOLOGIC STATE OF PATIENTS WITH RHEUMATIC DISEASES AFTER THE OUTBREAK OF SARS-COV2 M. Yasmine, S. Mariem, S. Miladi, A. Fazaa, L. Souebni, K. Ouenniche, et al. (+4)
145 [GO] 2021―May―26 AB0654 TOCILIZUMAB IS PROTECTIVE AGAINST SARS-COV2 INFECTION OR NOT? F. Fayed, E. Abdelkarim
146 [GO] 2021―May―26 AB0699 RETROSPECTIVE ANALYSIS OF 52 SARS-COV2 POSITIVE PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE: A SINGLE CENTER EXPERIENCE Y. Karabulut
147 [GO] 2021―May―26 AB0684 LESS THAN 20% OF PATIENTS WITH A CHRONIC INFLAMMATORY RHEUMATIC DISEASE CHANGED THEIR IMMUNOSUPPRESSIVE MEDICATION BECAUSE OF THE COVID 19 PANDEMIC I. Andreica, R. Jast, G. Rezniczek, U. Kiltz, D. Kiefer, B. Buehring, et al. (+2)
148 [GO] 2021―May―26 AB0905-HPR TELEMEDICINE IN RHEUMATOLOGY AT TIME OF COVID PANDEMIC G. Cuomo, F. Masini, K. Gjeloshi, D. Lubrano, L. E. Adinolfi, C. Romano
149 [GO] 2021―May―26 AB0926-PARE IMPACT OF COVID 19 PANDEMIC ON TUNISIAN SPA PATIENTS: PSYCHOLOGICAL STATE AND TREATMENT ADHERENCE M. Rachdi, A. Feki, Z. Gassara, S. Ben Jemaa, M. Ghali, M. Ezzeddine, et al. (+4)
150 [GO] 2021―May―26 AB0879-HPR MOTIVATION OF HEALTHCARE PROVIDERS DURING COVID19 PANDEMIC OUTBREAK C. Cobilinschi, A. Constantinescu, I. Draniceanu, A. Balanescu, V. Bojinca, C. L. Constantinescu, et al. (+7)
151 [GO] 2021―May―25 POS0047 OUTCOMES IN INFLAMMATORY ARTHROPATHY PATIENTS HOSPITALIZED FOR COVID-19 T. Collins, V. Patel, A. Babajanians, S. Kubomoto
152 [GO] 2021―May―25 OP0288 MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY Z. Izadi, M. Gianfrancesco, K. Hyrich, A. Strangfeld, L. Gossec, L. Carmona, et al. (+27)
153 [GO] 2021―May―25 OP0282 RITUXIMAB ASSOCIATED WITH SEVERE COVID-19 AMONG PATIENTS WITH INFLAMMATORY ARTHRITIDES: A 1-YEAR MULTICENTER STUDY IN 1116 SUCCESSIVE PATIENTS RECEIVING BIOLOGIC AGENTS R. Felten, P. M. Duret, E. Bauer, M. Ardizzone, H. J. Djossou, J. H. Salmon, et al. (+9)
154 [GO] 2021―May―25 OP0314 DOCK8 MUTATIONS IN COVID-19 AND MIS-C CYTOKINE STORM SYNDROME R. Cron, M. Zhang, D. Absher, J. Bridges, A. Schnell, P. Bhatraju, et al. (+5)
155 [GO] 2021―May―25 OP0284 OUTCOME OF COVID-19 IN PATIENTS WITH RHEUMATIC AND INFLAMMATORY DISEASES TREATED WITH RITUXIMAB: DATA FROM DE FRENCH RMD COVID-19 COHORT J. Avouac, E. Drumez, E. Hachulla, R. Seror, S. Georgin-Lavialle, S. El Mahou, et al. (+17)
156 [GO] 2021―May―25 OP0324-PARE PATIENT INFORMATION IN TIMES OF CRISIS: LESSONS LEARNED FROM COVID-19 COMMUNICATION IN RHEUMATOLOGY M. M. Bakker, T. Luttikhuis, I. Jansen, J. Rademakers, M. De Wit, A. Boonen, P. Putrik
157 [GO] 2021―May―25 POS0053 RHEUMATOID ARTHRITIS AND THE RISK OF COVID-19 DIAGNOSIS, HOSPITALISATION AND DEATH: A POPULATION-BASED MULTI-STATE COHORT ANALYSIS INCLUDING 5,586,565 PEOPLE IN CATALONIA, SPAIN A. Vivekanantham, E. Burn, S. Fernandez-Bertolin, M. Aragon, T. Duarte-Salles, D. Prieto-Alhambra
158 [GO] 2021―May―25 OP0006 ASSOCIATIONS OF BASELINE USE OF BIOLOGIC OR TARGETED SYNTHETIC DMARDS WITH COVID-19 SEVERITY IN RHEUMATOID ARTHRITIS: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE J. Sparks, Z. Wallace, A. Seet, M. Gianfrancesco, Z. Izadi, K. Hyrich, et al. (+36)
159 [GO] 2021―May―25 OP0286 CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA) M. F. Ugarte-Gil, G. S. Alarcon, A. Seet, Z. Izadi, C. Reategui Sokolova, A. E. Clarke, et al. (+44)
160 [GO] 2021―May―25 POS0051 THE IMPACT OF COVID-19 ON RHEUMATOLOGY TRAINING: RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE TRAINEE SURVEY K. Young, S. A. Yeoh, M. Putman, E. Graef, F. Berenbaum, R. Conway, et al. (+13)
161 [GO] 2021―May―25 OP0082-PARE THE EFFECT COVID-19 HAS ON THE MENTAL HEALTH OF PEOPLE LIVING WITH RHEUMATIC DISEASES. FROM DATA TO INTERVENTIONS. S. Mingolla, A. Celano, M. Santopietro
162 [GO] 2021―May―25 OP0285 COVID-19 HOSPITALIZATIONS, ICU ADMISSION, AND DEATH AMONG PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) - A POPULATION-BASED STUDY L. Eder, R. Croxford, A. Drucker, A. Mendel, K. Bindee, Z. Touma, et al. (+5)
163 [GO] 2021―May―25 OP0283 DOES TNF-INHIBITION DECREASE THE RISK OF SEVERE COVID-19 IN RMD-PATIENTS? R. Hasseli, B. F. Hoyer, A. Krause, H. M. Lorenz, A. Pfeil, A. Regierer, et al. (+7)
164 [GO] 2021―May―25 POS0054 THE IMPACT AND OUTCOME OF COVID-19 ON SYSTEMIC SCLEROSIS PATIENTS FROM THE EUROPEAN SCLERODERMA TRIAL AND RESEARCH GROUP (EUSTAR) A. M. Hoffmann-Vold, C. Brunborg, F. Tirelli, P. Carreira, N. Del Papa, A. Mekinian, et al. (+15)
165 [GO] 2021―May―25 POS1258 MISSING THE WINDOW OF OPPORTUNITY: EARLY ARTHRITIS CLINICS IN TIMES OF COVID-19 B. D’onofrio, L. De Stefano, B. L. Palermo, B. Xoxi, A. Manzo, C. Montecucco, S. Bugatti
166 [GO] 2021―May―25 POS1257 HYPOGAMMAGLOBULINEMIA IS A SIGNIFICANT RISK FACTOR FOR MORTALITY IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS AND COVID-19 B. Ince, M. Bektas, N. Koca, B. F. Agargun, S. Zarali, D. Y. Guzey, et al. (+4)
167 [GO] 2021―May―25 POS1251 ROLE OF SYSTEMIC AUTOINMUNE CONDITIONS IN HOSPITAL ADMISSIONS RELATED TO COVID-19 I. Perez-Sancristobal, L. Lopez Pedraza, M. P. Álvarez Hernandez, J. I. Colomer, A. Madrid García, B. Fernandez, et al. (+5)
168 [GO] 2021―May―25 OP0274-PARE EVALUATION OF PATIENT SATISFACTION FOR TELEHEALTH (PHONE AND VIDEO) IN RHEUMATOLOGY OUTPATIENTS DURING COVID-19 PANDEMIC Y. Oh, A. Hennessey, L. Young, D. Yates, C. Barrett
169 [GO] 2021―May―25 OP0264-HPR “I LITERALLY CONVINCED MYSELF I WAS GOING TO CATCH IT AND DIE”: LIVED EXPERIENCES OF THE COVID-19 PANDEMIC BY PEOPLE WITH RHEUMATIC DISEASES FROM FOUR EUROPEAN COUNTRIES R. J. O. Ferreira, C. Costa, A. Marques, A. J. Barata Cavaleiro, S. Makri, K. Parperis, et al. (+5)
170 [GO] 2021―May―25 POS0056 ANXIETY AND CONCERNS RELATED TO THE WORK SITUATION DURING THE COVID-19 PANDEMIC IN >5,000 PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE FOLLOWED IN THE DANISH DANBIO REGISTRY, RESULTS FROM A NATIONWIDE QUESTIONNAIRE B. Glintborg, D. V. Jensen, S. Engel, L. Terslev, M. Pfeiffer Jensen, O. Hendricks, et al. (+15)
171 [GO] 2021―May―25 OP0265-HPR IMPACT OF COVID-19 PANDEMIC ON RHEUMATOLOGY PATIENTS IN NORTHERN IRELAND - A WEB BASED CROSS-SECTIONAL SURVEY P. McKee, A. Irvine, C. Riddell, E. Ball
172 [GO] 2021―May―25 POS0152-HPR REMOTE CLINICAL MANAGEMENT: INCORPORATING ELECTRONIC ASSESSMENT OF PATIENTS WITH RHEUMATIC DISEASES INTO STANDARD CLINICAL PATHWAYS DURING THE COVID-19 PANDEMIC: A PILOT STUDY T. Malley, J. Jackman, S. Manderson, L. Saldana Pena, E. Evans, J. Barrett, et al. (+2)
173 [GO] 2021―May―25 LB0001 MAVRILIMUMAB IMPROVES OUTCOMES IN PHASE 2 TRIAL IN NON-MECHANICALLY-VENTILATED PATIENTS WITH SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPERINFLAMMATION L. Pupim, T. S. Wang, K. Hudock, J. Denson, N. Fourie, L. Hercilla Vasquez, et al. (+12)
174 [GO] 2021―May―25 OP0281 EXCESS GIANT CELL ARTERITIS CASES ARE ASSOCIATED WITH PEAKS IN COVID-19 PREVALENCE B. Mulhearn, J. Ellis, S. Skeoch, J. Pauling, S. Tansley
175 [GO] 2021―May―25 POS1237 ALGORITHM IDENTIFYING CHRONIC INFLAMMATORY DISEASES TREATED BY BIOTHERAPY AND/OR TARGETED SYNTHETIC TREATMENTS IN OUTPATIENT CARE IN FRANCE: FEASIBILITY, PRELIMINARY RESULTS, AND IMPACT OF COVID-19 P. Richette, M. Allez, V. Descamps, L. Perra, S. Pilet, M. Maravic
176 [GO] 2021―May―25 POS1228 THE ROLE OF CHEST CT IN UNDERSTANDING INTERSTITIAL LUNG DISEASE (ILD): SYSTEMIC SCLEROSIS (SSc). VERSUS COVID-19 M. Orlandi, N. Landini, G. Sambataro, C. Nardi, C. Bruni, S. Bellando-Randone, et al. (+25)
177 [GO] 2021―May―25 POS0050 ARE PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) MORE LIKELY TO RECEIVE COVID-19 TESTS AND TEST POSITIVE FOR SARS-COV-2? A MATCHED POPULATION-BASED STUDY L. Eder, R. Croxford, A. Drucker, A. Mendel, K. Bindee, Z. Touma, et al. (+5)
178 [GO] 2021―May―25 LB0003 IMMUNOGENICITY AND SAFETY OF THE BNT162b2 mRNA COVID-19 VACCINE IN ADULT PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES AND GENERAL POPULATION: A MULTICENTER STUDY V. Furer, T. Eviatar, D. Zisman, H. Peleg, D. Paran, D. Levartovsky, et al. (+23)
179 [GO] 2021―May―25 OP0009-PARE SUCCESSFUL PATIENT EDUCATION ON COVID-19 VACCINE SAFETY IN A LARGE RHEUMATOLOGY COHORT USING INTERACTIVE MOBILE-PHONE VIDEO TECHNOLOGY: CONTEXT, RESULTS, AND NEXT STEPS L. Rajagopala, M. Ford, M. Jasim, D. Mulherin, S. Venkatachalam, T. Sheeran, J. Bateman
180 [GO] 2021―May―25 LB0002 COVID-19 VACCINE SAFETY IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASE P. M. Machado, S. Lawson-Tovey, K. Hyrich, L. Carmona, L. Gossec, E. Mateus, et al. (+17)
181 [GO] 2021―May―25 POS1223 RAS GUANYL RELEASING PROTEIN 1 (RASGRP1) IN PERIPHERAL B CELLS LINKS RA TO COVID-19 S. Hannawi, F. Alqutami, M. Y. Hachim
182 [GO] 2021―May―25 OP0287 IMMUNOMODULATORY THERAPIES FOR SEVERE FORMS OF COVID-19: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER A. Alunno, A. Najm, X. Mariette, J. Emmel, L. Mason, G. De Marco, et al. (+2)
183 [GO] 2021―May―25 POS1177 REVAMPING BIOLOGIC THERAPY DURING COVID-19 S. Ahmed Narikkoottungal, A. Siddiqui, A. Constantin, S. Farrow, K. Ahmed
184 [GO] 2021―May―25 POS0052 PATHOPHYSIOLOGY OF ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER A. Najm, A. Alunno, X. Mariette, B. Terrier, G. De Marco, L. Mason, et al. (+3)
185 [GO] 2021―May―25 OP0313 PRELIMINARY CRITERIA FOR MACROPHAGE ACTIVATION SYNDROME ASSOCIATED WITH CORONAVIRUS DISEASE-19 S. Amikishiyev, M. G. Gunver, M. Bektas, S. Aghamuradov, B. Ince, N. Koca, et al. (+24)
186 [GO] 2021―May―25 POS1163 CHARACTERISTICS AND OUTCOMES IN A REAL-WORLD COHORT OF RHEUMATOID ARTHRITIS PATIENTS WITH COVID-19 Y. Ye, X. Yue, W. Krueger, L. Wegrzyn
187 [GO] 2021―May―25 POS0349 SEQUENCE COMPLEMENTARITY BETWEEN SARS-CoV-2 GENOME AND HUMAN NONCODING RNAS ASSOCIATED WITH IMMUNOLOGICAL DISORDERS: AN IN SILICO PIVOTAL STUDY R. Talotta, S. Bahrami, M. J. Laska
188 [GO] 2021―May―25 POS0049 SARS-COV-2 INFECTION IN CHILDREN WITH RHEUMATIC DISEASE: EXPERIENCE OF A TERTIARY REFERRAL CENTER B. Sözeri, F. Demir, S. Kalin, C. Hasbal Akkuş
189 [GO] 2021―May―25 POS0055 SARS-COV-2 OUTBREAK IN AUTOIMMUNE DISEASES: THE EURO-COVIMID STUDY D. Saadoun, M. Vieira, M. Vautier, X. Baraliakos, I. Andreica, J. A. P. Da Silva, et al. (+16)
190 [GO] 2021―May―25 OP0075 EVALUATION OF A VIRTUAL REALITY TEACHING CONCEPT FOR MEDICAL STUDENTS DURING THE SARS-COV-2 PANDEMIC A. Pfeil, F. Marcus, T. Hoffmann, P. Klemm, P. Oelzner, U. Müller-Ladner, et al. (+6)
191 [GO] 2021―May―25 OP0323-PARE “CELEBRATING THE 50TH ANNIVERSARY OF OUR ORGANISATION IN TIMES OF PANDEMIC: HOW WE USED DIGITAL TOOLS TO OVERCOME CHALLENGES AND DIFFICULTIES AND CAME INTO CONTACT WITH MORE PARTICIPANTS AND VIEWERS THAN EVER ENVISAGED!” C. Elling-Audersch
192 [GO] 2021―May―25 POS1235 ASSESSMENT OF RISK FACTORS FOR HOSPITALIZATION OF AUTOIMMUNE AND RHEUMATIC DISEASE PATIENTS WITH COVID-19 - A SINGLE CENTRE OBSERVATIONAL STUDY J. M N, P. Dekate, S. Vontari, R. Dudam
193 [GO] 2021―May―25 POS1264 IMMUNE-MEDIATED DISEASES (IMID) AND CORONAVIRUS DISEASE 2019 (COVID-19): RESULTS FROM AN OBSERVATIONAL RETROSPECTIVE MULTICENTER STUDY R. Dos-Santos, C. Calviño, I. Bastón, R. Ferreiro, F. Montero, C. Gonzalez, et al. (+3)
194 [GO] 2021―May―25 POS1190 EXPECTATIONS AND POTENTIAL CONCERNS OF PATIENTS WITH AUTOIMMUNE AND RHEUMATIC DISEASES REGARDING VACCINATION AGAINST SARS-CoV-2 (COVID-19): THE WORLDWIDE ONLINE VAXICOV STUDY R. Felten, M. Dubois, M. F. Ugarte-Gil, J. Fort, L. Pijnenburg, A. Chaudier, et al. (+10)
195 [GO] 2021―May―25 POS1172 COVID-19 ACROSS RHEUMATOLOGY: A BIBLIOMETRIC STUDY B. Doskaliuk, R. Yatsyshyn, I. Stoika, K. Fedorovych, O. Drogomeretska, O. Hotsaniuk, Y. Delva
196 [GO] 2021―May―25 POS1210 PREVALENCE OF COVID-19 AMONG PATIENTS WITH RHEUMATIC DISEASES: AN OBSERVATIONAL SURVEY DURING THE TWO WAVES IN ITALY S. Fasano, I. Pantano, D. Mauro, D. Capocotta, D. Iacono, E. Gaggiano, et al. (+6)
197 [GO] 2021―May―25 POS1211 IDENTIFICATION OF COMMON FUNCTIONAL PATHWAYS IN PATIENTS WITH LUPUS AND COVID-19 BY TIME-SERIES ANALYSIS Y. LI, S. X. Zhang, J. Qiao, Q. Wang, S. Song, R. Zhao, et al. (+7)
198 [GO] 2021―May―25 POS1168 SELF-REPORTED SARS-CoV2 TESTING AND COVID-19 DISEASE IN PATIENTS WITH RHEUMATOID ARTHRITIS, AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS IN A SWISS OBSERVATIONAL COHORT E. Papagiannoulis, A. Ciurea, D. Dan, A. Finckh, B. Gilbert, I. Von Loga, et al. (+3)
199 [GO] 2021―May―25 POS1263 COVID-19 FROM THE PATIENTS’S PERSPECTIVE: PRELIMINARY RESULTS OF ONLINE SURVEY D. Karateev, P. Pchelnikova, E. Luchikhina, T. Boboshko
200 [GO] 2021―May―25 POS1162 PREDICTORS OF HOSPITALISATION IN PATIENTS WITH RHEUMATIC DISEASE AND COVID-19 IN IRELAND: DATA FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE PHYSICIAN-REPORTED REGISTRY R. Conway, E. Nikiphorou, C. Demetriou, C. Low, K. Leamy, J. Ryan, et al. (+11)
201 [GO] 2021―May―25 POS1201 Incidence and outcome of COVID-19 in ANCA-associated vasculitis: impact of COVID-19 in patients undergoing rituximab for maintenance E. Treppo, M. Binutti, G. Del Frate, S. De Vita, L. Quartuccio
202 [GO] 2021―May―25 POS1181 CLINICAL COURSE OF COVID-19 IN CHILDREN WITH RHEUMATIC DISEASE UNDER BIOLOGIC THERAPY F. Demir, K. Ulu, Ş. Çağlayan, T. Coşkuner, B. Sözeri
203 [GO] 2021―May―25 POS1202 EXPERIENCE WITH COVID-19 IN GERMAN PAEDIATRIC RHEUMATOLOGY CENTRES A. Klein, D. Windschall, W. Emminger, R. Berendes, J. Kuemmerle-Deschner, R. Trauzeddel, et al. (+10)
204 [GO] 2021―May―25 POS1233 USE OF BARICITINIB AND TOCILIZUMAB FOR THE TREATMENT OF MODERATE TO SEVERE COVID-19 IN HOSPITALIZED PATIENTS D. X. Xibille Friedmann, S. M. Carrillo Vazquez
205 [GO] 2021―May―25 POS1246 COVID-19 IN ITALIAN PATIENTS WITH RHEUMATIC AUTOIMMUNE SYSTEMIC DISEASES: RESULTS OF A NATIONWIDE SURVEY STUDY C. Ferri, D. Giuggioli, V. Raimondo, L. Dagna, V. Riccieri, E. Zanatta, et al. (+60)
206 [GO] 2021―May―25 POS1242 FACTORS ASSOCIATED WITH MORTALITY IN PATIENTS WITH RHEUMATIC DISEASES AND COVID-19 IN MEXICO D. Alpizar-Rodriguez, F. Irazoque-Palazuelos, T. S. Rodriguez-Reyne, E. Zamora, D. X. Xibille Friedmann, A. Castillo Ortiz, et al. (+24)
207 [GO] 2021―May―25 POS1193 CLINICAL FEATURES AND THE COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER A. Avanoglu Guler, T. Yüce İnel, H. Karadeniz, R. Bilici Salman, H. Satiş, H. Küçük, et al. (+6)
208 [GO] 2021―May―25 POS1259 FAVOURABLE SHORT-TERM COURSE OF COVID-19 IN PATIENTS WITH FAMILIAL MEDITERRANEAN FEVER USING BIOLOGIC AGENTS N. Aliyeva, B. Ç. Yalçin Dulundu, S. Amikishiyev, S. Aghamuradov, M. Bektaş, B. Ince, et al. (+5)
209 [GO] 2021―May―25 POS1247 CLINICAL FEATURES AND OUTCOMES OF COVID-19 IN PATIENTS WITH IGG4-RELATED DISEASE. A COLLABORATIVE EUROPEAN MULTI-CENTRE STUDY G. A. Ramirez, M. Lanzillotta, M. Ebbo, A. Fernandez-Codina, G. Mancuso, F. Martínez-Valle, et al. (+5)
210 [GO] 2021―May―25 POS1227 IMPACT OF A PRE-EXISTING INTERSTITIAL LUNG DISEASE ON SEVERITY OF COVID-19 IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES P. A. Juge, E. Hachulla, C. Richez, E. Drumez, A. Duhamel, R. Borie, P. Dieudé
211 [GO] 2021―May―25 POS1252 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES ON CHRONIC USE OF HYDROXYCHLOROQUINE IN A LARGE BRAZILIAN COHORT - A 24-WEEK PROSPECTIVE STUDY G. Salviato Pileggi, G. Ferreira, A. P. Gomides, E. Reis Neto, M. Abreu, C. Albuquerque, et al. (+33)
212 [GO] 2021―May―25 POS1188 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON OF DATA FROM THE ARGENTINE REGISTRY (SAR-COVID), WITH THE LATIN AMERICAN AND GLOBAL REGISTRY (GLOBAL RHEUMATOLOGY ALLIANCE) A. A. Reyes, G. Alle, R. Tanten, M. Scolnik, E. Soriano, G. Berbotto, et al. (+21)
213 [GO] 2021―May―25 POS1245 MORTALITY OF COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: COMPARISON TO THE GENERAL POPULATION IN MÉXICO M. U. Martínez-Martínez, F. Irazoque-Palazuelos, T. S. Rodriguez-Reyne, E. Zamora, A. Castillo Ortiz, B. E. Zazueta, et al. (+13)
214 [GO] 2021―May―25 POS1266 COVID-19 IN PATIENTS WITH RHEUMATIC DISEASES: SURVEY-BASED ASSESSMENT OF THE RISK OF HOSPITALIZATION D. Karateev, P. Pchelnikova, E. Luchikhina, T. Boboshko
215 [GO] 2021―May―25 POS1226 THE COURSE OF CORONAVIRUS DISEASE 2019 (COVID-19) IN PATIENTS WITH SJOGREN’S SYNDROME TREATED WITH ANTI-CD20 MONOCLONAL ANTIBODY (RITUXIMAB) E. Sokol, A. Torgashina, B. Chalcev, J. Khvan, O. Golovina
216 [GO] 2021―May―25 POS1232 COVID-19 IN PATIENTS WITH SYSTEMIC SCLEROSIS: ONE RHEUMATOLOGY CENTER EXPERIENCE M. Starovoytova, O. Desinova, L. P. Ananyeva, O. Koneva, L. Garzanova, O. Ovsyannikova, et al. (+3)
217 [GO] 2021―May―25 POS1161 A CITIZEN SCIENCE APPROACH TO CAPTURE POOR MENTAL HEALTH RELATED TO COVID-19 IN RHEUMATIC PATIENTS AFTER CONFINEMENT DURING PANDEMIC IN ITALY F. Ingegnoli, M. Buoli, C. Posio, R. DI Taranto, A. Lo Muscio, E. Cumbo, et al. (+2)
218 [GO] 2021―May―25 POS1254 INCIDENCE AND OUTCOME OF COVID-19 IN ROUTINE RHEUMATOLOGY CARE: DATA FROM A SINGLE OUTPATIENT CENTER IN GERMANY S. G. Werner, P. Höhenrieder, R. Chatelain, H. E. Langer
219 [GO] 2021―May―25 POS1184 AUTOIMMUNE SYSTEMIC DISEASES AND COVID-19 INFECTION S. Monov, R. Shumnalieva, D. Monova
220 [GO] 2021―May―25 POS1198 THE ROLE OF SOCS3 IN COLCHICINE ANTI-INFLAMMATORY EFFECT ON COVID-19 INFECTION M. Y. Hachim, F. Alqutami, S. Hannawi
221 [GO] 2021―May―25 POS1215 INFLUENCE OF CONFINEMENT CARRIED OUT BY PATIENTS WITH AUTOIMMUNE AND IMMUNE- MEDIATED INFLAMMATORY DISEASE WITH BIOLOGICAL TREATMENT ON COVID-19 INFECTION J. Font-Urgelles, S. Mínguez, B. Rodríguez-Diez, L. Creus-Vila, M. Esquius Rafat, X. Fusta Novell, et al. (+5)
222 [GO] 2021―May―25 POS1183 OUTCOMES OF COVID-19 INFECTION AMONG CHILDREN AND YOUNG PEOPLE WITH PRE-EXISTING RHEUMATIC AND MUSCULOSKELETAL DISEASES L. Kearsley-Fleet, S. Lawson-Tovey, R. E. Costello, A. Belot, F. Aeschlimann, I. Melki, et al. (+15)
223 [GO] 2021―May―25 POS1230 OUTCOME FOLLOWING COVID-19 INFECTION IN ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY (ANCA)-ASSOCIATED VASCULITIS A. Antovic, B. Lövström, A. Hugelius, O. Borjesson, A. Bruchfeld, I. Gunnarsson
224 [GO] 2021―May―25 POS1231 COVID-19 INFECTION IN RHEUMATIC IMMUNE-MEDIATED INFLAMMATORY DISEASES. EPIDEMIOLOGICAL STUDY IN A SINGLE UNIVERSITY HOSPITAL D. Martínez-López, D. Prieto-Peña, L. Sanchez-Bilbao, A. Herrero-Morant, C. Álvarez-Reguera, M. Trigueros-Vazquez, et al. (+2)
225 [GO] 2021―May―25 POS1234 IMPACT OF THE CHANGE IN ADMINISTRATION ROUTE OF TOCILIZUMAB AND ABATACEPT, DUE TO THE COVID-19 LOCKDOWN ON DISEASE ACTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS L. Diebold, T. Wirth, V. Pradel, N. Balandraud, E. Fockens, C. Paris, et al. (+3)
226 [GO] 2021―May―25 POS1189 THE IMPACT OF TELEMEDICINE AND COVID-19 ON A TERTIARY RHEUMATOLOGY SERVICE: A RETROSPECTIVE AUDIT W. Zhu, T. De Silva, L. Eades, S. Morton, S. Ayoub, E. F. Morand, A. Antony
227 [GO] 2021―May―25 POS1236 IMPACT OF COVID-19 ON INITIATION AND RENEWAL OF BIOTHERAPIES AND TARGETED SYNTHETIC TREATMENTS P. Richette, M. Allez, V. Descamps, L. Perra, S. Pilet, M. Maravic
228 [GO] 2021―May―25 POS1205 THE IMPACT OF COVID-19 ON PATIENT MANAGEMENT AND PRESCRIBING STRATEGY ACROSS THE EU AND US: A REAL-WORLD SURVEY OF RHEUMATOLOGISTS, DERMATOLOGISTS, AND GASTROENTEROLOGISTS E. Holdsworth, R. Lukanova, M. Hughes, J. Hall, J. Austin, G. Taylor-Stokes, J. Piercy
229 [GO] 2021―May―25 POS1192 BEHAVIOR AND FEELINGS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DURING LOCKDOWN MEASURES FOR THE COVID-19 OUTBREAK G. De Marchi, D. Azzolina, E. Maresio, D. Colatutto, M. Binutti, M. Monte, et al. (+7)
230 [GO] 2021―May―25 POS1222 FACTORS ASSOCIATED WITH USE OF TELEMEDICINE FOR FOLLOW-UP OF LUPUS NEPHRITIS IN THE COVID-19 OUTBREAK H. So, E. Chow, T. K. LI, I. T. Cheng, S. L. Lau, C. C. Szeto, L. S. Tam
231 [GO] 2021―May―25 POS1164 USE OF TELEMEDICINE FOR FOLLOW-UP OF SLE PATIENTS WITH NEPHRITIS IN THE COVID-19 OUTBREAK (“TeleSLE”): THE 6-MONTH RESULTS OF A RANDOMIZED CONTROLLED TRIAL H. So, E. Chow, T. K. LI, S. L. Lau, I. T. Cheng, C. C. Szeto, L. S. Tam
232 [GO] 2021―May―25 POS1207 REAL WORLD POPULATION-BASED ASSESSMENT OF COVID-19 OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS USING BIOLOGIC OR SYNTHETIC DMARDs L. Wegrzyn, K. Winthrop, S. Kim, Y. Ye, C. Huisingh, W. Krueger, et al. (+2)
233 [GO] 2021―May―25 POS1186 EFFECT OF SOCIO-ECONOMIC STATUS AND EDUCATIONAL LEVEL ON COVID-19 OUTCOMES IN PATIENTS WITH RHEUMATIC DISEASES FROM ARGENTINA: DATA FROM THE SAR-COVID REGISTRY L. Sorrentino, J. Rebak, F. Maldonado, V. V. Castro Coello, A. Brigante, A. Hamaui, et al. (+22)
234 [GO] 2021―May―25 POS1166 UNDERSTANDING PRESCRIPTION BEHAVIOR ACROSS HEALTHCARE PROFESSIONALS IN TREATING KNEE OSTEOARTHRITIS BEFORE AND DURING THE 2020 COVID-19 PANDEMIC D. Baldock, E. Baynton, H. Hamdan
235 [GO] 2021―May―25 POS1173 A SHORT DELAY IN ARTHRITIS CARE IS ASSOCIATED WITH HIGHER DISEASE ACTIVITY - LESSONS FROM THE CORONAVIRUS DISEASE 19 (COVID-19) PANDEMIC A. Giollo, E. Bertoldo, C. Benini, O. Viapiana, L. Idolazzi, G. Adami, et al. (+3)
236 [GO] 2021―May―25 POS1178 THE ROLE OF VIRTUAL TELEPHONE VISITS IN THE TIGHT CONTROL OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH TARGETED THERAPIES DURING THE COVID-19 PANDEMIC F. Ingegnoli, G. Cincinelli, A. F. Luppino, E. Favalli, R. Caporali
237 [GO] 2021―May―25 POS1244 PRELIMINARY RESULTS OF LONG-TERM FOLLOW-UP OF THE HEALTH STATUS OF PATIENTS USING csDMARDs AND b/tsDMARDS FOR RHEUMATIC DISEASES DURING THE COVID-19 PANDEMIC F. Unlu Ozkan, K. Sari, I. Aktas
238 [GO] 2021―May―25 POS1265 CHALLENGES OF EGYPTIAN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS DURING COVID-19 PANDEMIC S. Tharwat, S. Zohdy
239 [GO] 2021―May―25 POS1243 TELEMEDICINE AND MANAGEMENT OF THE PATIENT AFFECTED BY GIANT CELL ARTERITIS DURING THE COVID-19 PANDEMIC - TELEMACOV S. Parisi, M. C. Ditto, A. Laganà, C. L. Peroni, E. Fusaro
240 [GO] 2021―May―25 POS1213 IMPACT OF THE COVID-19 PANDEMIC AND LOCKDOWN ON WELLBEING ON PATIENTS WITH RHEUMATIC DISEASES. RESULTS FROM THE REUMAVID STUDY (PHASE 1) M. Garrido-Cumbrera, H. Marzo-Ortega, L. Christen, L. Carmona, J. Correa-Fernández, S. Sanz-Gómez, et al. (+10)
241 [GO] 2021―May―25 POS1175 ASSESSMENT OF THE COVID-19 PANDEMIC FROM THE PERSPECTIVE OF PEOPLE WITH RHEUMATIC MUSCULOSKELETAL DISEASES IN EUROPE. RESULTS FROM THE REUMAVID STUDY (PHASE 1) M. Garrido-Cumbrera, H. Marzo-Ortega, J. Correa-Fernández, S. Sanz-Gómez, L. Christen, V. Navarro-Compán
242 [GO] 2021―May―25 POS1170 SELF-PROTECTION STRATEGIES, HEALTH BEHAVIOR AND DISEASE ACTIVITY DURING THE FIRST WAVE, RE-OPENING AND SECOND WAVE OF THE COVID-19 PANDEMIC IN >7000 DANISH PATIENTS WITH INFLAMMATORY ARTHRITIS B. Glintborg, D. V. Jensen, S. Engel, L. Terslev, M. Pfeiffer Jensen, O. Hendricks, et al. (+15)
243 [GO] 2021―May―25 POS1249 MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN DURING THE COVID-19 PANDEMIC IN TURKEY: FIRST REPORT FROM THE EASTERN MEDITERRANEAN Y. Ozsurekci, S. Gürlevik, S. Kesici, U. Kaya Akca, P. D. Oygar, K. Aykac, et al. (+12)
244 [GO] 2021―May―25 POS1169 IMPACT OF THE COVID-19 PANDEMIC ON MORBIDITY AND MORTALITY AMONG SWEDISH PATIENTS WITH INFLAMMATORY JOINT DISEASES VERSUS THE GENERAL POPULATION H. Bower, T. Frisell, D. DI Giuseppe, B. Delcoigne, G. M. Alenius, E. Baecklund, et al. (+10)
245 [GO] 2021―May―25 POS1241 THE IMPACT OF THE COVID-19 PANDEMIC ON PHYSICAL FUNCTIONING AND MENTAL WELLBEING IN 824 PATIENTS WITH RHEUMATIC DISEASE OVER 8 MONTHS: PHYSICAL FUNCTIONING DECLINES N. Cleaton, S. Raizada, T. Sheeran, J. Bateman
246 [GO] 2021―May―25 POS1167 REVIEW OF THE IMPACT OF COVID-19 PANDEMIC ON RHEUMATOLOGY SERVICES AT A LARGE TERTIARY CARE CENTRE IN WALES, UK R. Asif, N. Elndari, A. Negi
247 [GO] 2021―May―25 POS1185 IMPACT OF LOCKDOWN DURING COVID-19 PANDEMIC ON THE ONSET OF POST-TRAUMATIC STRESS DISORDER (PTSD) IN SYSTEMIC SCLEROSIS PATIENTS: A CASE-CONTROL STUDY D. M. Reza Beigi, G. Pellegrino, A. Lorello, C. Angelelli, K. Stefanantoni, F. Conti, V. Riccieri
248 [GO] 2021―May―25 POS1171 THE COVID-19 PANDEMIC PROMPTS ISOLATION AND BEHAVIORAL CHANGES IN PATIENTS WITH CHRONIC RHEUMATIC DISEASES LEADING TO REDUCED PHYSICAL ACTIVITY, INCREASED PAIN, DISEASE ACTIVITY, AND LOW SEROPREVALENCE OF SARS-CoV2 ANTIBODIES C. Ammitzbøll, J. B. Andersen, S. R. Vils, C. M. Jørgensen, E. M. Hauge, C. Erikstrup, et al. (+3)
249 [GO] 2021―May―25 POS1182 MANAGEMENT OF DIFFICULT-TO-TREAT RHEUMATOID ARTHRITIS DURING THE COVID-19 PANDEMIC: EVIDENCE FROM THE ITALIAN EPICENTER F. Ingegnoli, A. F. Luppino, G. Cincinelli, E. Favalli, R. Caporali
250 [GO] 2021―May―25 POS1261 DISEASE ACTIVITY AND PAIN LEVELS ARE NOT INFLUENCED BY THE CURRENT COVID19 PANDEMIC IN PATIENTS WITH RHEUMATIC DISEASES IN GERMANY - DATA FROM THE GERMAN COVID-19 PATIENT SURVEY R. Hasseli, U. Müller-Ladner, T. Schmeiser, H. M. Lorenz, A. Krause, H. Schulze-Koops, et al. (+7)
251 [GO] 2021―May―25 POS1250 VITAMIN D DEFICIENCY IS MAINLY ASSOCIATED WITH SEVERE LUNG INVOLVEMENT, LONGER DISEASE DURATION AND RISK OF DEATH IN ELDERLY COVID-19 PATIENTS A. Sulli, E. Gotelli, A. Casabella, M. Grosso, C. Schenone, C. Pizzorni, et al. (+4)
252 [GO] 2021―May―25 POS1224 RHEUMATIC MANIFESTATIONS IN COVID-19 PATIENTS - SINGLE-CENTER EXPERIENCE AMIDST THE PANDEMIC S. Bogdanova-Petrova, T. Georgiev, G. Gerganov, S. Hristova, S. Dimitrov, T. Shivacheva
253 [GO] 2021―May―25 POS1256 SINGLE DOSE TOCILIZUMAB PHARMACOKINETICS IN GLUCOCORTICOID PRE-TREATED COVID-19 PATIENTS DURING CYTOKINE STORM SYNDROME HYPERINFLAMMATORY EPISODE: LESS IS MORE N. Boone, S. Ramiro, D. J. Moes, R. Mostard, C. Magro Checa, C. Van Dongen, et al. (+6)
254 [GO] 2021―May―25 POS1214 THE DYNAMICS OF INFLAMMATORY MARKERS IN COVID-19 PATIENTS TREATED WITH LEVILIMAB N. Lomakin, B. Bakirov, G. Musaev, D. Protsenko, O. Moiseeva, E. Pasechnik, et al. (+13)
255 [GO] 2021―May―25 POS1209 SUCCESSFUL TREATMENT OF SEVERE COVID-19 PNEUMONIA AND CYTOKINE RELEASE WITH SIMULTANEOUS TOCILIZUMAB AND ANAKINRA WITH ONE-MONTH FOLLOW-UP H. Haibel, J. L. Vahldiek, S. Angermair, M. Schumann, B. Siegmund, D. Poddubnyy, T. Schneider
256 [GO] 2021―May―25 POS1176 THE IMPACT OF COVID-19 QUARANTINE ON MENTAL HEALTH OF PATIENTS WITH FIBROMYALGIA F. Ingegnoli, M. Buoli, C. Posio, R. DI Taranto, R. Caporali
257 [GO] 2021―May―25 POS1262 A COHORT STUDY OF COVID-19 RELATED MULTISYSTEM INFLAMMATORY SYNDROME IN CHILDREN AND ADOLESCENTS FROM MULTIPLE TERTIARY CARE CENTRES IN SOUTH INDIA A. Tiwari, A. Rauf, S. Kesavan, M. Kappanayil, S. Sivadas, S. Balan, P. Chickermane
258 [GO] 2021―May―25 POS1197 IN DEPTH IDENTIFICATION OF RISK FACTORS FOR SEVERE COVID-19, REQUIRING HOSPITALIZATION, IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: RESULTS OF A DUTCH NESTED CASE CONTROL STUDY (PRELIMINARY RESULTS) M. Opdam, S. Benoy, L. M. Verhoef, S. Van Bijnen, F. Lamers-Karnebeek, R. A. M. Traksel, et al. (+3)
259 [GO] 2021―May―25 POS1191 COVID-19 STRESS: DOES IT AUGMENT PAIN IN PEOPLE WITH FIBROMYALGIA AND MIGHT PSYCHOLOGICAL FLEXIBILITY PROTECT AGAINST THIS INFLUENCE? T. Koppert, J. W. G. Jacobs, M. Lumley, R. Geenen
260 [GO] 2021―May―25 POS1187 WILLINGNESS TO GET THE COVID-19 VACCINE AMONG PATIENTS WITH RHEUMATIC DISEASES, HEALTH WORKERS AND GENERAL POPULATION B. Yurttas, B. C. Poyraz, N. Süt, A. Ozdede, M. Oztas, Ö. F. Tabak, et al. (+2)
261 [GO] 2021―May―25 POS1268 COVID-19 VACCINE HESITANCY AMONG RHEUMATOLOGY PATIENTS RECEIVING INFLUENZA VACCINE V. Valerio, H. C. Shen, E. Field, E. G. Mcdonald, A. Turner, S. Bernatsky, et al. (+2)
262 [GO] 2021―May―25 POS1248 SAFETY PROFILE OF PFIZER-BIONTECH COVID-19 VACCINE IN PATIENTS WITH RHEUMATIC DISEASES: PRELIMINARY ASSESSMENT G. Cuomo, M. Atteno, C. Naclerio, L. E. Adinolfi, C. Romano
263 [GO] 2021―May―25 POS1196 COVID-19 VACCINE WILLINGNESS IN RA? RESULTS FROM THE RA LOUVAIN BRUSSELS COHORT T. Sokolova, V. Pirson, T. Xavier, E. Curraj, L. Bricman, E. Sapart, et al. (+4)
264 [GO] 2021―May―25 POS1220 PREGNANT AND POSTPARTUM WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES AND COVID-19: A CASE SERIES R. A. Rodriguez Chavez, C. M. Skinner Taylor, L. Pérez Barbosa, G. Figueroa-Parra, J. E. Compeán-Villegas, L. G. Espinosa Banuelos, et al. (+4)
265 [GO] 2021―May―25 POS1174 HYPERINFLAMMATION AND CLINICAL OUTCOMES FOR PATIENTS WITH SYSTEMIC RHEUMATIC DISEASES HOSPITALIZED FOR COVID-19: A COMPARATIVE COHORT STUDY T. Hsu, K. D’silva, N. Serling-Boyd, J. Wang, A. Mueller, X. Fu, et al. (+10)
266 [GO] 2021―May―25 POS1238 ANTIPHOSPHOLIPID ANTIBODIES AND COVID-19: TREND OVER TIME S. Mancuso, S. Truglia, A. Capozzi, F. Pasquali, S. Recalchi, G. Riitano, et al. (+6)
267 [GO] 2021―May―25 POS1314 JUVENILE IDIOPATHIC ARTHRITIS IN THE CONTEXT OF THE CORONAVIRUS DISEASE 19 PANDEMIC: IMPACT ON THE DECREASE IN TREATMENT AND THE RETURN TO SCHOOL B. Quéré, I. Lemelle, A. Lohse, P. Pillet, J. Molimard, O. Richer, et al. (+8)
268 [GO] 2021―May―25 POS1195 ASSESSING ANTIBODY STATUS FOR SARS-CoV-2 IN PEOPLE WITH CORONAVIRUS INFECTION: A TIME COURSE STUDY IN PEOPLE WITH AUTOIMMUNE CONDITIONS K. Biddle, S. Koushesh, A. Blundell, D. Clark, S. Krishna, N. Sofat
269 [GO] 2021―May―25 POS1206 SEROPREVALENCE OF SARS-CoV-2 ANTIBODIES IN AUTOIMMUNE INFLAMMATORY RHEUMATOLOGIC PATIENTS T. Eviatar, D. Levartovsky, V. Furer, A. Polachek, O. Elalouf, M. Zisapel, et al. (+6)
270 [GO] 2021―May―25 POS1212 SARS-CoV-2 INFECTION AMONG PATIENTS WITH BEHÇET’S SYNDROME I. Mattioli, A. Bettiol, M. L. Urban, E. Silvestri, D. Malandrino, A. Palermo, et al. (+3)
271 [GO] 2021―May―25 POS1267 CLINICAL COURSE OF NEW SARS-COV-2 INFECTION IN CHILDREN WITH RHEUMATIC DISEASES: RETROSPECTIVE STUDY OF SINGLE PEDIATRIC RHEUMATOLOGY CENTER I. Nikishina, Z. Kolkhidova, V. Matkava, A. Shapovalenko, S. Arsenyeva, M. Kaleda, et al. (+2)
272 [GO] 2021―May―25 POS1260 FACTORS ASSOCIATED WITH SEVERE SARS-COV-2 INFECTION IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES IN MADRID: RESULTS FROM REUMA-COVID SORCOM REGISTRY A. Boteanu, A. García Fernández, N. De la Torre, M. Pavia Pascual, O. Sanchez Pernaute, S. Recuero Diaz, et al. (+9)
273 [GO] 2021―May―25 POS1208 EPIDEMIOLOGY AND OUTCOMES OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE ARGENTINEAN SAR-COVID REGISTRY C. A. Isnardi, R. Quintana, K. Roberts, V. V. Castro Coello, A. A. Reyes, Y. Tissera, et al. (+15)
274 [GO] 2021―May―25 POS1194 THE EFFECT OF SARS-COV-2 ON THE COURSE AND THE TREATMENT OF RHEUMATIC INFLAMMATORY DISEASES. EXPERIENCE FORM THE NORTHWESTERN GREECE E. Pelechas, E. Kaltsonoudis, M. Migos, P. Karagianni, A. Kavvadias, P. Voulgari, A. Drosos
275 [GO] 2021―May―25 POS1229 ANTI-MDA5 AND ANTISYNTHETASE ANTIBODIES SCREENING IN SEVERE SARS-COV-2 PNEUMONIA. BE AWARE OF FALSE POSITIVE RESULTS A. Gil-Vila, J. Perurena-Prieto, C. Nolla-Fontana, O. Orozco-Galvez, M. Miarons-Font, A. Guillén del Castillo, et al. (+4)
276 [GO] 2021―May―25 POS1219 SARS-COV-2 VACCINE HESITANCY AMONG PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES: A MESSAGE FOR RHEUMATOLOGISTS R. Priori, G. Pellegrino, S. Colafrancesco, C. Alessandri, F. Ceccarelli, M. DI Franco, et al. (+5)
277 [GO] 2021―May―25 POS1255 REACTOGENICITY OF SARS-COV-2 VACCINES IN PATIENTS WITH AUTOIMMUNE AND INFLAMMATORY DISEASE M. Yang, P. Katz, D. Paez, A. Carvidi, M. Matloubian, M. Nakamura, L. S. Gensler
278 [GO] 2021―May―25 POS1180 TREATMENT COMPLIANCE OF PATIENTS WITH RHEUMATOID ARTHRITIS DURING THE FIRST WAVE OF THE SARS-CoV-2/COVID-19 PANDEMIC IN PORTUGAL: RESULTS FROM THE COVID IN RA (COVIDRA) SURVEY F. Araujo, N. Gonçalves, A. F. Mourão
279 [GO] 2021―May―25 POS1204 LOW POSITIVITY RATE IN ANTIBODY SARS-COV2 TESTS IN PATIENTS WITH RHEUMATIC DISEASES TREATED WITH RITUXIMAB. A CASE CONTROL STUDY OF A HIGH IMPACT SARS-COV2 INFECTION AREA. A. García Fernández, P. Morán Álvarez, J. Bachiller-Corral, M. Vázquez Díaz
280 [GO] 2021―May―25 POS1218 SAFETY AND EFFICACY OF ANAKINRA IN SEVERE SARS-COV2 INFECTION (COVID19) AT A TERTIARY HOSPITAL O. Rusinovich, A. Mora, E. Muñez, L. Delgado Tellez de Cepeda, N. De la Torre, M. Pavía, et al. (+4)
281 [GO] 2021―May―25 POS1199 CLINICAL MANIFESTATIONS OF SARS-CoV2 INFECTIONS IN CHILDREN AND ADOLESCENTS WITH RHEUMATIC AND MUSCULUSKELETAL DISEASES - SURVEY DATA FROM GERMANY C. Sengler, S. Eulert, M. Niewerth, T. Kallinich, H. Wittkowski, H. Girschick, et al. (+10)
282 [GO] 2021―May―25 POS1216 SYMPTOM RATES, ATTITUDES AND MEDICATION ADHERENCE OF RHEUMATIC AND MUSCULOSKELETAL DISEASE PATIENTS DURING THE SARS-CoV2 PANDEMIC K. Murray, S. Quinn, M. Turk, A. O’rourke, E. Molloy, L. O’neill, et al. (+3)
283 [GO] 2021―May―25 POS1221 SARS-COV2 SEROLOGY SCREENING IN SPONDYLOARTHRITIS PATIENTS IN NORTH-EASTERN ITALY: A PILOT STUDY A. Ortolan, C. Cosma, M. Lorenzin, G. Cozzi, A. Doria, M. Plebani, R. Ramonda
284 [GO] 2021―May―25 POS1217 THE PATTERN OF COVID 19 PANDEMIC AMONG PATIENTS WITH AUTOIMMUNE INFLAMMATORY RHEUMATIC DISEASES (AIIRD) F. Kharouf, T. Eviatar, M. Braun, E. Pokroy-Shapira, M. Brodavka, N. Agmon-Levin, et al. (+17)
285 [GO] 2021―May―25 POS1203 EFFECT OF THE COVID19 PANDEMIC ON RHEUMATOLOGIST PRESCRIPTION BEHAVIOUR OF NEW ADVANCED THERAPY: DATA OF THE TARDIS-RA REGISTRY, A NATIONWIDE BELGIAN BIOLOGIC REGISTRY D. De Cock, P. Durez, V. Badot, R. Westhovens, P. Verschueren
286 [GO] 2021―May―24 High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases Jake A Ruddy, Caoilfhionn Marie Connolly, Brian J Boyarsky, William A Werbel, Lisa Christopher-Stine, Jacqueline Garonzik-Wang, et al. (+2)
287 [GO] 2021―May―13 Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Rosenbaum et al Kimme L Hyrich, Martin Schäfer, Anja Strangfeld, Loreto Carmona, Laure Gossec, Elsa F Mateus, et al. (+5)
288 [GO] 2021―May―13 Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’ James Todd Rosenbaum, Michael H Weisman, Cassie Shafer, Elin Aslanyan, Richard A Howard, Kimberly Ogle, et al. (+4)
289 [GO] 2021―May―12 Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’ Desiree Tampe, Peter Korsten, Samy Hakroush, Martin Sebastian Winkler, Björn Tampe
290 [GO] 2021―May―12 Response to: ‘Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’’ by Tampe et al Marcia A Friedman, Kevin L Winthrop
291 [GO] 2021―May―06 Antibody response to SARS-CoV-2 in patients receiving glucocorticoids with or without tocilizumab for COVID-19-associated hyperinflammation Marlou T H F Janssen, Sofia Ramiro, Robert B M Landewé, César Magro-Checa, Rémy L M Mostard
292 [GO] 2021―May―06 SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response Michael Markus Bonelli, Daniel Mrak, Thomas Perkmann, Helmuth Haslacher, Daniel Aletaha
293 [GO] 2021―May―06 SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases David Simon, Koray Tascilar, Filippo Fagni, Gerhard Krönke, Arnd Kleyer, Christine Meder, et al. (+15)
294 [GO] 2021―Apr―27 Response to: ‘Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’’ by Roongta et al Veerle F A M Derksen, Diane van der Woude
295 [GO] 2021―Apr―27 EULAR COVID-19 registry: lessons learnt and future considerations Saskia Lawson-Tovey, Anja Strangfeld, Kimme L Hyrich, Loreto Carmona, Diana Rodrigues, Laure Gossec, et al. (+2)
296 [GO] 2021―Apr―27 Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’ Rashmi Roongta, Arghya Chattopadhyay, Alakendu Ghosh
297 [GO] 2021―Apr―27 Correspondence on ‘EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs’ Serena Bugatti, Silvia Balduzzi, Ludovico De Stefano, Antonio Manzo, Blerina Xoxi, Laura Bogliolo, et al. (+3)
298 [GO] 2021―Apr―27 Response to: ‘Correspondence on ‘EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs’’ by Bugatti et al Johannes W J Bijlsma
299 [GO] 2021―Apr―26 Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients Uriel Trahtemberg, Robert Rottapel, Claudia C Dos Santos, Arthur S Slutsky, Andrew Baker, Marvin J Fritzler
300 [GO] 2021―Apr―26 Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ Aimilios Kaklamanos, Panagiotis Karamichalos, Panayiotis G Vlachoyiannopoulos, Athanasios G Tzioufas
301 [GO] 2021―Apr―26 Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Kaklamanos et al Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
302 [GO] 2021―Apr―13 Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy Francesca Ingegnoli, Gilberto Cincinelli, Angela Flavia Luppino, Ennio Giulio Favalli, Annalisa Orenti, Patrizia Boracchi, Roberto Caporali
303 [GO] 2021―Apr―13 Prospective study into COVID-19-like symptoms in patients with and without immune-mediated inflammatory diseases or immunomodulating drugs Lotte van Ouwerkerk, Andrea E van der Meulen-de Jong, Maarten K Ninaber, Y K Onno Teng, Tom WJ Huizinga, Cornelia F Allaart
304 [GO] 2021―Apr―09 Correspondence on ‘Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study’ Liang En Wee, Edwin Philip Conceicao, Jing Yuan Tan, Julian Thumboo, Indumathi Venkatachalam
305 [GO] 2021―Mar―23 Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases Brian J Boyarsky, Jake A Ruddy, Caoilfhionn M Connolly, Michael T Ou, William A Werbel, Jacqueline M Garonzik-Wang, et al. (+2)
306 [GO] 2021―Mar―19 Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases Caoilfhionn M Connolly, Jake A Ruddy, Brian J Boyarsky, Robin K Avery, William A Werbel, Dorry L Segev, et al. (+2)
307 [GO] 2021―Mar―16 SARS-CoV-2 infection among inpatients with systemic lupus erythematosus in France: a nationwide epidemiological study Arthur Mageau, Geoffrey Aldebert, Damien Van Gysel, Thomas Papo, Jean-François Timsit, Karim Sacre
308 [GO] 2021―Mar―10 Correspondence on ‘SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease’ Shanoj K C, Sakir Ahmed, Veena Shenoy, Aparna R Menon, Sanjo Saijan, Sageer AS Babu, Padmanabha Shenoy
309 [GO] 2021―Mar―10 Response to: ‘Correspondence on ‘SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease’’ by Shanoj et al Kristin M D’Silva, Naomi Serling-Boyd, Tiffany Y-T Hsu, Jeffrey A Sparks, Zachary Scott Wallace
310 [GO] 2021―Mar―05 Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab Marcia A Friedman, Kevin L Winthrop
311 [GO] 2021―Mar―03 Rheumatology and COVID-19 at 1 year: facing the unknowns Leonard Calabrese, Kevin L Winthrop
312 [GO] 2021―Mar―03 Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Charles Josef S Smolen
313 [GO] 2021―Mar―01 Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’’ by Mulhearn et al Martin Schäfer, Anja Strangfeld, Kimme L Hyrich, Loreto Carmona, Milena Gianfrancesco, Saskia Lawson-Tovey, et al. (+5)
314 [GO] 2021―Mar―01 Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’ Ben Mulhearn
315 [GO] 2021―Mar―01 Onset of rheumatoid arthritis after COVID-19: coincidence or connected? Veerle F A M Derksen, Theresa Kissel, Femke B G Lamers-Karnebeek, Arie E van der Bijl, Annemarie C Venhuizen, Tom W J Huizinga, et al. (+3)
316 [GO] 2021―Feb―23 Impact of the COVID-19 pandemic on morbidity and mortality in patients with inflammatory joint diseases and in the general population: a nationwide Swedish cohort study Hannah Bower, Thomas Frisell, Daniela Di Giuseppe, Bénédicte Delcoigne, Gerd-Marie Ahlenius, Eva Baecklund, et al. (+10)
317 [GO] 2021―Feb―23 SARS-CoV-2 vaccine hesitancy among patients with rheumatic and musculoskeletal diseases: a message for rheumatologists Roberta Priori, Greta Pellegrino, Serena Colafrancesco, Cristiano Alessandri, Fulvia Ceccarelli, Manuela Di Franco, et al. (+5)
318 [GO] 2021―Feb―18 Response to: ‘Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician reported registry’ by Arnaud and Devilliers Pedro M Machado, Martin Schäfer, Anja Strangfeld, Laure Gossec, Milena Gianfrancesco, Saskia Lawson-Tovey, et al. (+5)
319 [GO] 2021―Feb―18 Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry’ Laurent Arnaud, Hervé Devilliers
320 [GO] 2021―Feb―16 Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ Maria De Santis, Antonio Voza, Victor Savevski, Salvatore Badalamenti, Maurizio Cecconi, Alberto Mantovani, Carlo Selmi
321 [GO] 2021―Feb―16 Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by De Santis et al Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
322 [GO] 2021―Feb―16 Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider Alessia Alunno, Aurélie Najm, Xavier Mariette, Gabriele De Marco, Jenny Emmel, Laura Mason, et al. (+2)
323 [GO] 2021―Feb―15 Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ Pierre Charles
324 [GO] 2021―Feb―15 Response to: ’Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’’ by Charles Sofia Ramiro, Rémy L M Mostard, Robert B M Landewé
325 [GO] 2021―Feb―10 EULAR December 2020 View points on SARS-CoV-2 vaccination in patients with RMDs Johannes WJ Bijlsma
326 [GO] 2021―Feb―07 EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19 Alessia Alunno, Aurélie Najm, Pedro M Machado, Heidi Bertheussen, Gerd R Burmester, Francesco Carubbi, et al. (+18)
327 [GO] 2021―Jan―29 PASTUL questionnaire: a tool for self-assessment of scleroderma skin during the COVID-19 pandemic Julia Spierings, Voon Ong, Christopher P Denton
328 [GO] 2021―Jan―28 Correspondence on ‘Anti-inflammatory therapy for COVID-19 infection: the case for colchicine’ Carlo Perricone, Elena Bartoloni, Giacomo Cafaro, Roberto Caporali, Roberto Gerli
329 [GO] 2021―Jan―28 Response to: ‘Correspondence on ‘Anti-inflammatory therapy for COVID-19 infection: the case for colchicine’’ by Perricone et al Binita Shah, Aaron Z Reyes, Kelly A Hu, Jacob Teperman, Theresa L Wampler Muskardin, Jean-Claude Tardif, Michael H Pillinger
330 [GO] 2021―Jan―28 Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ Shamma Al Nokhatha, Neil MacEoin, Richard Conway
331 [GO] 2021―Jan―28 Response to: ‘Correspondence on ‘Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries’ by Nokhatha et al Christian Dejaco, Johannes WJ Bijlsma, Frank Buttgereit
332 [GO] 2021―Jan―28 Potential acceptance of COVID-19 vaccine in rheumatological patients: a monocentric comparative survey Corrado Campochiaro, Giorgia Trignani, Alessandro Tomelleri, Stefano Cascinu, Lorenzo Dagna
333 [GO] 2021―Jan―27 Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Anja Strangfeld, Martin Schäfer, Milena A Gianfrancesco, Saskia Lawson-Tovey, Jean W Liew, Lotta Ljung, et al. (+31)
334 [GO] 2021―Jan―27 Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Lee Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
335 [GO] 2021―Jan―27 Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’ Young Ho Lee
336 [GO] 2021―Jan―27 Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’ Tomoyuki Kawada
337 [GO] 2021―Jan―27 Response to: ‘Correspondence on ‘Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome’’ by Kawada Silvia Piantoni, Laura Andreoli, Enrico Colombo, Monia Mendeni, Maria Laura Ghirardelli, Antonio Brucato, et al. (+5)
338 [GO] 2021―Jan―25 CO0004 OLDER AGE, CARDIOVASCULAR COMORBIDITY AND GLUCOCORTICOSTEROIDS ARE RISK FACTORS FOR COVID-19 HOSPITALISATION IN PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASES: FIRST RESULTS OF THE GERMAN COVID-19-IRD REGISTRY A. Regierer, R. Hasseli, B. Hoyer, A. Krause, H. M. Lorenz, A. Pfeil, et al. (+7)
339 [GO] 2021―Jan―25 CO0001 MAVRILIMUMAB IMPROVES OUTCOMES IN SEVERE COVID-19 PNEUMONIA AND SYSTEMIC HYPER-INFLAMMATION G. De Luca, G. Cavalli, C. Campochiaro, E. Della Torre, P. Angelillo, A. Tomelleri, et al. (+15)
340 [GO] 2021―Jan―25 CO0005 C-C CHEMOKINE RECEPTOR TYPE 5 AND ITS LIGANDS CCL4, 8 AND 11 CAN LINK COVID-19, RHEUMATOID ARTHRITIS AND HYDROXYCHLOROQUINE M. Y. Hachim, S. Hannawi
341 [GO] 2021―Jan―25 CO0002 LOSS OF SELF-TOLERANCE IN SARS-COV-2 INFECTION: IMMUNOLOGICAL ASSESSMENT OF A CONVALESCENT COHORT A. Paglionico, V. Varriano, B. Tolusso, S. Alivernini, L. Petricca, G. Natalello, et al. (+5)
342 [GO] 2021―Jan―25 C00006 PSYCHOLOGICAL IMPACT OF COVID 19 PANDEMIC ON PATIENTS WITH RHEUMATOLOGICAL DISORDERS - A WEB BASED CROSS-SECTIONAL MULTICENTRE SURVEY Y. G C, Y. P. Singh, S. Prasad, N. Srinivasulu, S. Kumar, S. R, et al. (+4)
343 [GO] 2021―Jan―21 Correspondence on ‘Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients’ Tanaz A Kermani
344 [GO] 2021―Jan―21 Use of non-steroidal anti-inflammatory drugs and risk of death from COVID-19: an OpenSAFELY cohort analysis based on two cohorts Angel YS Wong, Brian MacKenna, Caroline E Morton, Anna Schultze, Alex J Walker, Krishnan Bhaskaran, et al. (+26)
345 [GO] 2021―Jan―15 Correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ Sarthak Gupta, Shuichiro Nakabo, Jun Chu, Sarfaraz Hasni, Mariana J Kaplan
346 [GO] 2021―Jan―15 Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et al Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
347 [GO] 2021―Jan―15 Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’ Haiyan Yang, Jie Xu, Li Shi, Guangcai Duan, Yadong Wang
348 [GO] 2021―Jan―13 SARS-CoV-2 antibody response after COVID-19 in patients with rheumatic disease Kristin M D’Silva, Naomi Serling-Boyd, Tiffany Y-T Hsu, Jeffrey A Sparks, Zachary S Wallace
349 [GO] 2021―Jan―07 Correspondence on ‘Preliminary predictive criteria for COVID-19 cytokine storm’ Desiree Tampe, Martin S Winkler, Peter Korsten, Samy Hakroush, Onnen Moerer, Björn Tampe
350 [GO] 2021―Jan―07 Response to: ‘Correspondence on ‘Preliminary predictive criteria for COVID-19 cytokine storm’’ by Tampe et al Roberto Caricchio, Marcello Gallucci, Chandra Dass, Xinyan Zhang, Stefania Gallucci, David Fleece, et al. (+2)
351 [GO] 2021―Jan―06 Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic-World Scleroderma Foundation preliminary advice for patient management’ Elena Snarskaya, Kseniia Vasileva
352 [GO] 2021―Jan―06 Response to: ‘Correspondence on ‘Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management’’ by Snarskaya and Vasileva Cosimo Bruni, Marco Matucci-Cerinic
353 [GO] 2021―Jan―05 Prevalence, admission rates and hypoxia due to COVID-19 in patients with rheumatic disorders treated with targeted synthetic or biologic disease modifying antirheumatic drugs or methotrexate: a nationwide study from Iceland Aron Hjalti Bjornsson, Gerdur Grondal, Mar Kristjansson, Thorunn Jonsdottir, Thorvardur Jon Love, Bjorn Gudbjornsson
354 [GO] 2020―Dec―22 Correspondence on ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’ Sibel Zehra Aydin, Elliot Hepworth, Peter Tugwell
355 [GO] 2020―Dec―22 Response to: ‘Correspondence on ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’’ by Aydin et al Dalifer Dayanira Freites Nuñez, Leticia Leon, Arkaitz Mucientes, Luis Rodriguez-Rodriguez, Judit Font Urgelles, Alfredo Madrid García, et al. (+4)
356 [GO] 2020―Dec―18 Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine Alexis Mathian, Matthieu Mahevas, Julien Rohmer, Mathilde Roumier, Fleur Cohen-Aubart, Blanca Amador-Borrero, et al. (+29)
357 [GO] 2020―Dec―18 Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management Marco Matucci-Cerinic, Cosimo Bruni, Yannick Allanore, Massimo Clementi, Lorenzo Dagna, Nemanja S Damjanov, et al. (+14)
358 [GO] 2020―Dec―18 Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic Hendrik Schulze-Koops, Christof Specker, Christof Iking-Konert, Julia Holle, Frank Moosig, Klaus Krueger
359 [GO] 2020―Dec―16 Response to: ‘Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19- associated cytokine storm syndrome: results of the CHIC study’’ by Calvo-Aranda et al Sofia Ramiro, Rémy Mostard, Robert BM Landewé
360 [GO] 2020―Dec―16 Correspondence on ‘Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study’ Enrique Calvo-Aranda, Irene Cañamares-Orbis, Marta Novella-Navarro, Alvaro Martinez-Alcala, Maria del Carmen Ortega de la O, Ismael Escobar-Rodriguez, Fernando Manuel Sanchez-Aranda
361 [GO] 2020―Dec―08 Anti-inflammatory therapy for COVID-19 infection: the case for colchicine Aaron Z Reyes, Kelly A Hu, Jacob Teperman, Theresa L Wampler Muskardin, Jean-Claude Tardif, Binita Shah, Michael H Pillinger
362 [GO] 2020―Dec―02 Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients
363 [GO] 2020―Nov―30 Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic Naomi Serling-Boyd, Kristin M D’Silva, Tiffany YT Hsu, Rachel Wallwork, Xiaoqing Fu, Ellen M Gravallese, et al. (+5)
364 [GO] 2020―Nov―25 Response to: ‘Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al’ by Notz et al Alexis Mathian, Zahir Amoura
365 [GO] 2020―Nov―20 Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al ’ by Ventura et al Juliette Chommeloux, Marie Pouletty, Naim Ouldali, Mathieu Kerneis, Alexis Mathian, Raphaele Mestiri, et al. (+3)
366 [GO] 2020―Nov―17 COVID-19 cytokine storm: what is in a name? Peter A Nigrovic
367 [GO] 2020―Nov―12 Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’ Cloé Comarmond, Mathilde Leclercq, Gaëlle Leroux, Cindy Marques, Alexandre Le Joncour, Fanny Domont, et al. (+10)
368 [GO] 2020―Nov―12 Response to: ‘Correspondence on ‘Impact of COVID-19 pandemic on patients with large-vessels vasculitis in Italy: a monocentric survey’ by Comarmond et al Alessandro Tomelleri, Silvia Sartorelli, Elena Marina Baldissera, Lorenzo Dagna, Corrado Campochiaro
369 [GO] 2020―Nov―11 Response to ‘Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort’ by Ruyssen-Witrand et al Adrian Ciurea, Axel Finckh
370 [GO] 2020―Nov―11 Correspondence on ‘Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort’ Adeline Ruyssen-Witrand, Martin Soubrier, André Basch, Marie-Elise Truchetet, Raphaèle Seror
371 [GO] 2020―Nov―10 Response to ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Shi et al Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
372 [GO] 2020―Nov―10 Correspondence on ‘prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’ Jiyuan Shi, Ya Gao, Lili Zhang, Yang Zhao, Jianguo Xu, Jinhui Tian
373 [GO] 2020―Nov―06 Influence of COVID-19 pandemic on decisions for the management of people with inflammatory rheumatic and musculoskeletal diseases: a survey among EULAR countries Christian Dejaco, Alessia Alunno, Johannes WJ Bijlsma, Annelies Boonen, Bernard Combe, Axel Finckh, et al. (+5)
374 [GO] 2020―Nov―03 Response to ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Gremese et al Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
375 [GO] 2020―Nov―03 Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’ Elisa Gremese, Giovanni Brondani, Luca Apollonio, Gianfranco Ferraccioli
376 [GO] 2020―Nov―02 Clinical course of COVID-19 in a cohort of 342 familial Mediterranean fever patients with a long-term treatment by colchicine in a French endemic area Rim Bourguiba, Marion Delplanque, Caroline Vinit, Léa Savey, Gilles Grateau, Veronique Hentgen, Sophie Georgin-lavialle
377 [GO] 2020―Oct―30 Neither earlier nor late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study Sergey Moiseev, Sergey Avdeev, Ekaterina Tao, Michail Brovko, Nikolay Bulanov, Anastasiia Zykova, et al. (+3)
378 [GO] 2020―Oct―30 Response to ‘Neither earlier not late tocilizumab improved outcomes in the intensive care unit patients with COVID-19 in a retrospective cohort study’ by Moiseev et al Sofia Ramiro, Robert B M Landewé, Rémy Mostard
379 [GO] 2020―Oct―30 Correspondence to ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’ Hendrik Schulze-Koops, Alla Skapenko, Andreas Krause, Klaus Krueger, Hanns-Martin Lorenz, Philipp Sewerin, et al. (+5)
380 [GO] 2020―Oct―30 Response to: ‘Correspondence on ‘Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases’’ by Schulze-Koops et al Dalifer Dayanira Freites Nuñez, Leticia Leon, Arkaitz Mucientes, Luis Rodriguez-Rodriguez, Judit Font Urgelles, Alfredo Madrid García, et al. (+4)
381 [GO] 2020―Oct―14 COVID-19 in Italian patients with rheumatic autoimmune systemic diseases Clodoveo Ferri, Dilia Giuggioli, Vincenzo Raimondo, Poupak Fallahi, Alessandro Antonelli
382 [GO] 2020―Oct―14 Trajectories of COVID-19 information in the Annals of the Rheumatic Diseases: the first months of the pandemic Kim Lauper, Johannes W J Bijlsma, Gerd R Burmester
383 [GO] 2020―Oct―13 Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis Shintaro Akiyama, Shadi Hamdeh, Dejan Micic, Atsushi Sakuraba
384 [GO] 2020―Oct―06 Response to ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID19): a multicentre cohort’’ by Mastrolia et al Charlotte Borocco, Marie Pouletty, Caroline Galeotti, Ulrich Meinzer, Albert Faye, Isabelle Koné-Paut, et al. (+2)
385 [GO] 2020―Oct―01 Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ Florence Jeny, Raphael Lhote, Gwenael Lorillon, Nicolas Belhomme, Grégory Pugnet, Raphaël Borie, et al. (+23)
386 [GO] 2020―Oct―01 Response to: ‘Correspondence on ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’’ by Jeny et al Andrea Hermina Györfi, Georg Schett, Jörg H W Distler
387 [GO] 2020―Sep―28 Tackling osteoarthritis during COVID-19 pandemic Francisco Airton Castro da Rocha, Lucas da Ponte Melo, Francis Berenbaum
388 [GO] 2020―Sep―25 Response to: ‘Correspondence to ‘Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases’’ by Wu et al Jose L Pablos, María Galindo, Ricardo Blanco, José M Alvaro-Gracia
389 [GO] 2020―Sep―25 Correspondence to ‘Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases’ Bo-Yao Wu, Chi-Ho Chan, James Cheng-Chung Wei
390 [GO] 2020―Sep―25 Preliminary predictive criteria for COVID-19 cytokine storm Roberto Caricchio, Marcello Gallucci, Chandra Dass, Xinyan Zhang, Stefania Gallucci, David Fleece, et al. (+2)
391 [GO] 2020―Sep―25 Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al Meredith J Ventura, Emmanuel Guajardo, Eva H Clark, Kalpana Bhairavarasu, Riyad Y Kherallah, Andrew R DiNardo, et al. (+4)
392 [GO] 2020―Sep―22 Impact of the COVID-19 pandemic on the disease course of patients with inflammatory rheumatic diseases: results from the Swiss Clinical Quality Management cohort Adrian Ciurea, Eleftherios Papagiannoulis, Kristina Bürki, Isabell von Loga, Raphael Micheroli, Burkhard Möller, et al. (+9)
393 [GO] 2020―Sep―22 Response to: ‘Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic’ by Lecler et al Sara Monti, Carlomaurizio Montecucco
394 [GO] 2020―Sep―21 Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: case-control study’ Martin Sebastian Winkler, Peter Korsten, Claudia Binder, Björn Tampe
395 [GO] 2020―Sep―21 Correspondence to ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ Maria Vincenza Mastrolia, Rino Agostiniani, Chiara Azzari, Roberto Bernardini, Ugo Bottone, Giovanni Battista Calabri, et al. (+16)
396 [GO] 2020―Sep―15 Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al. The impact of cardiovascular comorbidity on COVID-19 infection in a large cohort of rheumatoid arthritis patients Fabio Cacciapaglia, Andreina Manfredi, Gianluca Erre, Matteo Piga, Garifallia Sakellariou, ombretta viapiana, et al. (+4)
397 [GO] 2020―Sep―15 Paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS): what does the future hold? Murugan Sudhakar, Pandiarajan Vignesh
398 [GO] 2020―Sep―09 Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences’ by Ruscitti et al’ by Chen et al Piero Ruscitti, Federico Bruno, Onorina Berardicurti, Chiara Acanfora, Viktoriya Pavlych, Pierpaolo Palumbo, et al. (+10)
399 [GO] 2020―Sep―09 Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences’ by Ruscitti et al Acer I-Hung Chen, Sheng-Chieh Lin, James Cheng-Chung Wei
400 [GO] 2020―Sep―07 Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases Alessandro Giollo, Eugenia Bertoldo, Giovanni Adami, Adam J Cybulski, Angelo Fassio, Giovanni Orsolini, et al. (+4)
401 [GO] 2020―Sep―07 Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases’ by Giollo et al Kimme L Hyrich, Milena Gianfrancesco, Pedro M Machado, Jinoos Yazdany, Philip C Robinson
402 [GO] 2020―Sep―07 Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic Alireza Khabbazi, Hadiseh Kavandi, Roghayeh Paribanaem, Raha Khabbazi, Aida Malek Mahdavi
403 [GO] 2020―Sep―07 Education and treatment adherence during the COVID-19 pandemic. Response to: ‘Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic’ by Khabbazi et al Rita Angélica Pineda-Sic, Griselda Serna-Peña, Jesus Alberto Cardenas-de la Garza, Sergio A Torres-Castillo, Dionicio Angel Galarza-Delgado, Diana Elsa Flores-Alvarado
404 [GO] 2020―Sep―07 Response to: ‘Implications of SARS-CoV-2 infection for patients with rheumatic disease’ by Lin et al Alexis Mathian, Zahir Amoura
405 [GO] 2020―Sep―03 Response to ‘Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic’ by Chuah et al Alexis Mathian, Zahir Amoura
406 [GO] 2020―Sep―01 Response to: ‘Correspondence on ‘Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study’ by Potere et al’ by Buckley Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, et al. (+2)
407 [GO] 2020―Sep―01 Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study’ by Potere et al Leo Buckley
408 [GO] 2020―Aug―28 Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al Quirin Notz, Patrick Meybohm, Peter Kranke, Dirk Weismann, Christopher Lotz, Marc Schmalzing
409 [GO] 2020―Aug―28 Comment on ‘Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19’ by Konig et al. Long-term exposure to hydroxychloroquine or chloroquine and the risk of hospitalisation with COVID-19: a nationwide, observational cohort study in 54 873 exposed individuals and 155 689 matched unexposed individuals in France Emilie Sbidian, Laetitia Penso, Philippe Herlemont, Jérémie Botton, Bérangère Baricault, Laura Semenzato, et al. (+4)
410 [GO] 2020―Aug―28 Systemic lupus erythematosus and COVID-19: what we know so far Giuseppe A. Ramirez, Luca Moroni, Emanuel Della-Torre, Maria Gerosa, Lorenzo Beretta, Enrica P. Bozzolo, Lorenzo Dagna
411 [GO] 2020―Aug―27 Colchicine treatment in community healthcare setting to prevent severe COVID-19 Emanuel Della-Torre, Giuseppe A Ramirez, Lorenzo Dagna, Moreno Tresoldi
412 [GO] 2020―Aug―27 Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: ‘Colchicine treatment in community healthcare setting to prevent severe COVID-19’ by Della-Torre et al Silvia Piantoni, Enrico Colombo, Roberto Furloni, Laura Andreoli, Antonio Brucato, Massimo Imazio, et al. (+2)
413 [GO] 2020―Aug―19 Correspondence to: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al Rachael Mary Flood, Richard Conway, Colm Kirby, Diana Gheta, David J Kane, Ronan H Mullan
414 [GO] 2020―Aug―19 Challenge of diagnosing ANCA-associated vasculitis during COVID-19 pandemic: a missed ‘window of opportunity’ Alessandro Giollo, Riccardo Bixio, Davide Gatti, Ombretta Viapiana, Luca Idolazzi, Christian Dejaco, Maurizio Rossini
415 [GO] 2020―Aug―19 High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab Edoardo Conticini, Federico Franchi, David Bennett, Serafina Valente, Maria A Mazzei, Elena Bargagli, et al. (+3)
416 [GO] 2020―Aug―19 Response to: ‘High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab’ by Conticini et al Sofia Ramiro, Rémy Mostard, Robert BM Landewé
417 [GO] 2020―Aug―19 Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: ‘Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study’ by Della-Torre et al’ by Cheng and Zhang Emanuel Della-Torre, Giovanni Landoni, Alberto Zangrillo, Lorenzo Dagna
418 [GO] 2020―Aug―19 Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation-an open-label cohort study’ by Della-Torre et al Chao Cheng, Fangjie Zhang
419 [GO] 2020―Aug―18 Rheumatic diseases and COVID-19: a cohort of 17 patients under DMARDs. Response to: ‘Comment on: Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a COVID-19 patient with psoriatic arthritis receiving ustekinumab’ by Messina et al Pierre-Marie Duret, Lionel Spielmann, Laurent Messer
420 [GO] 2020―Aug―18 Comment on: Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept. A report on a patient with COVID-19 with psoriatic arthritis receiving ustekinumab Francesco Messina, Francesca Pampaloni, Stefano Piaserico
421 [GO] 2020―Aug―13 Implications of SARS-CoV-2 infection for patients with rheumatic disease Changsong Lin, Ziyu Wang, Jie Li, Xinyi Xia, Yun Liu, Qianghu Wang
422 [GO] 2020―Aug―12 Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study Jose L Pablos, María Galindo, Loreto Carmona, Ana Lledó, Miriam Retuerto, Ricardo Blanco, et al. (+9)
423 [GO] 2020―Aug―12 COVID-19 and how evidence of a new disease evolves Féline P B Kroon, Ted R Mikuls, Robert BM Landewé
424 [GO] 2020―Aug―12 COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al Milena Gianfrancesco, Kimme L Hyrich, Jinoos Yazdany, Pedro M Machado, Philip C Robinson
425 [GO] 2020―Aug―11 Impact of COVID-19 pandemic on hospitalisation of patients with systemic lupus erythematosus (SLE): report from a tertiary hospital during the peak of the pandemic Seow Lin Chuah, Cheng Lay Teh, Sharifah Aishah Wan Mohd Akbar, Yaw Kiet Cheong, Benjamin Sachdev Manjit Singh
426 [GO] 2020―Aug―11 Case of adult large vessel vasculitis after SARS-CoV-2 infection Ryohei Oda, Takeshi Inagaki, Masahiro Ishikane, Masatoshi Hotta, Akira Shimomura, Mitsuhiro Sato, et al. (+6)
427 [GO] 2020―Aug―10 High oligoclonality of immunoglobulins in SARS-CoV2 positive patients Marie Kolopp-Sarda, Pierre Miossec
428 [GO] 2020―Aug―07 Impact of lockdown on rheumatology outpatient care in the age of COVID-19 Benjamin Sachdev Manjit Singh, Seow Lin Chuah, Yaw Kiet Cheong, Sharifah Aishah Wan, Cheng Lay Teh
429 [GO] 2020―Aug―07 Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19 and the role of the rheumatologist’ by Graef et al Chien Hsien Lo, Yu-Hsun Wang, Chin Feng Tsai, Kuei Chuan Chan, Li Ching Li, Tse Hsien Lo, et al. (+2)
430 [GO] 2020―Aug―07 Mild COVID-19 in ANCA-associated vasculitis treated with rituximab Silvia Suárez-Díaz, Claudia Morán-Castaño, Rubén Coto-Hernández, Lourdes Mozo-Avellaneda, Carlos Suárez-Cuervo, Luis Caminal-Montero
431 [GO] 2020―Aug―07 Risk factors for hospital admissions related to COVID-19 in patients with autoimmune inflammatory rheumatic diseases Dalifer D Freites Nuñez, Leticia Leon, Arkaitz Mucientes, Luis Rodriguez-Rodriguez, Judit Font Urgelles, Alfredo Madrid García, et al. (+4)
432 [GO] 2020―Aug―07 Impact of the COVID-19 lockdown on the management and control of patients with GCA Roman Praliaud, Helene Greigert, Maxime Samson, Marianne Zeller, Mathieu Boulin, Philip Bielefeld, et al. (+3)
433 [GO] 2020―Aug―07 Increased rather than decreased incidence of giant-cell arteritis during the COVID-19 pandemic Augustin Lecler, Delphine Villeneuve, Catherine Vignal, Thomas Sené
434 [GO] 2020―Aug―07 Response to: ‘Correspondence on ‘Festina lente: hydroxychloroquine, COVID-19and the role of the rheumatologist’ by Graef et al’ by Lo et al Ali Duarte-García, Elizabeth R Graef, Jean W Liew, Maximilian F Konig, Alfred Hyoungju Kim, Jeffrey A Sparks
435 [GO] 2020―Aug―07 No increased rate of SARS-CoV-2 infection for patients with inflammatory rheumatic diseases compared with the general population in the city of Hamburg (Germany) Peer Aries, Christof Iking-Konert
436 [GO] 2020―Aug―05 Exacerbation of immune thrombocytopaenia triggered by COVID-19 in patients with systemic lupus erythematosus Yasushi Kondo, Yuko Kaneko, Tatsuhiro Oshige, Hiroyuki Fukui, Shuntaro Saito, Mikio Okayama, et al. (+5)
437 [GO] 2020―Aug―05 Response to: ‘Exacerbation of immune thrombocytopaenia triggered by COVID-19 in patients with systemic lupus erythematosus’ by Kondo et al Alexis Mathian, Zahir Amoura
438 [GO] 2020―Aug―05 COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs Khalil Ansarin, Ali Taghizadieh, Saeid Safiri, Aida Malek Mahdavi, Shirin Ranjbar, Soheil Teymouri, et al. (+2)
439 [GO] 2020―Aug―05 Response to: ‘Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future’ by Wang et al Janine A Lamb, Spyridon Megremis, Hector Chinoy
440 [GO] 2020―Aug―05 Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future Yukai Wang, Guangzhou Du, Guohong Zhang, Marco Matucci-Cerinic, Daniel E Furst
441 [GO] 2020―Aug―05 Hydroxychloroquin ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis Mendel E Singer, David C Kaelber, Maria J Antonelli
442 [GO] 2020―Aug―05 Response to: ‘Hydroxychloroquine ineffective for COVID-19 prophylaxis in lupus and rheumatoid arthritis’ by Singer et al Manuel Francisco Ugarte-Gil, Maximilian F Konig, Peter Korsten, Francis Berenbaum, Alfred Hyoungju Kim, Jeffrey A Sparks
443 [GO] 2020―Aug―05 Correspondence on: ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al Rosa Pino, Ana Carolina Izurieta, María Ríos-Barnés, Sílvia Ricart, Mariona F De Sevilla, Laura Monfort, et al. (+15)
444 [GO] 2020―Aug―05 Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al’ by Pino et al Naim Ouldali, Marie Pouletty, Johanna Lokmer, Cherine Benzouid, Constance Beyler, Anna Deho, et al. (+3)
445 [GO] 2020―Aug―04 To immunosuppress: whom, when and how? That is the question with COVID-19 Kevin L Winthrop, Xavier Mariette
446 [GO] 2020―Aug―04 Transient monoarthritis and psoriatic skin lesions following COVID-19 Ludovico De Stefano, Silvia Rossi, Carlomaurizio Montecucco, Serena Bugatti
447 [GO] 2020―Aug―04 Response to: ‘Presence of anti-phospholipid antibodies in COVID-19: a case series study’ by Amezcua-Guerra et al Alexis Mathian, Marc Pineton De Chambrun, Alain Combes, Zahir Amoura
448 [GO] 2020―Aug―04 Presence of antiphospholipid antibodies in COVID-19: case series study Luis M Amezcua-Guerra, Gustavo Rojas-Velasco, Malinalli Brianza-Padilla, Armando Vázquez-Rangel, Ricardo Márquez-Velasco, Francisco Baranda-Tovar, et al. (+6)
449 [GO] 2020―Aug―04 Treatment of patients with inflammatory rheumatic diseases with rituximab should be carefully considered during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Persistence of rT-PCR-SARS-CoV-2 infection and delayed serological response, as a possible effect of rituximab according to the hypothesis of Schulze-Koops et al’ by Benucci et al Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht Vallbracht, Rebecca Hasseli, Alla Skapenko
450 [GO] 2020―Jul―31 Rational use of tocilizumab in COVID-19 Siddharth Jain, Shefali Khanna Sharma
451 [GO] 2020―Jul―31 COVID-19 among Malaysian patients with systemic lupus erythematosus on hydroxychloroquine Cheng Lay Teh, Yaw Kiet Cheong, Wan Rosmaiza Wan Musa, Sharifah Aishah Wan Mohd Akbar, Noraini Mat Husin, Suk Chyn Gun
452 [GO] 2020―Jul―31 More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia Gianfranco Ferraccioli
453 [GO] 2020―Jul―31 Targeting IL-1, IL-6 or GM-CSF in COVID-19. Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli Emanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, Giacomo De Luca, Fabio Ciceri, Alberto Zangrillo, Lorenzo Dagna
454 [GO] 2020―Jul―31 Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma Pier Leopoldo Capecchi, Pietro Enea Lazzerini
455 [GO] 2020―Jul―31 Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, et al. (+2)
456 [GO] 2020―Jul―30 Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials - a real-world district general hospital experience Asim Khan, Alice Cole, Naveen Bhadauria, Munzir El-Hassan, Daud Abdulla, Thomas Axon, et al. (+4)
457 [GO] 2020―Jul―30 Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al Ioana Andreica, David Kiefer, Guenther A Rezniczek, Robert Jast, Bjoern Buehring, Uta Kiltz, et al. (+2)
458 [GO] 2020―Jul―30 Association between treatment with colchicine and improved survival in a single-centre cohort of adult hospitalised patients with COVID-19 pneumonia and acute respiratory distress syndrome Mirko Scarsi, Silvia Piantoni, Enrico Colombo, Paolo Airó, Donata Richini, Marco Miclini, et al. (+22)
459 [GO] 2020―Jul―28 Improving telemedicine and in-person management of rheumatic and autoimmune diseases,during and after COVID-19 pandemic outbreak. Definite need for more Rheumatologists. Response to: ‘Can telerheumatology improve rheumatic and musculoskeletal disease service delivery in sub-Saharan Africa?’ by Akpabio et al Francesco Caso, Antonio del Puente, Nicolò Girolimetto, Marco Tasso, Corrado Caso, Raffaele Scarpa, Luisa Costa
460 [GO] 2020―Jul―24 Response to: ‘Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in patients with rheumatism in Wuhan, China’’ by Chen et al Jixin Zhong, Cong Ye, Shaozhe Cai, Lingli Dong
461 [GO] 2020―Jul―24 Comment on Ye et al ‘Presence of respiratory failure of COVID-19 infection in rheumatism patients in Wuhan, China’ Xiao-Huan Chen, Chih-Jung Yeh, Han-You Mo, James Cheng Chung Wei
462 [GO] 2020―Jul―24 Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia Sharifah Aishah Wan, Cheng Lay Teh, Benjamin Sachdev Manjit Singh, Yaw Kiet Cheong, Seow Lin Chuah, Ahmad Tirmizi Jobli
463 [GO] 2020―Jul―24 Response to: ‘Clinical features of patients with rheumatic diseases and COVID-19 infection in Sarawak, Malaysia’ by Wan et al Jixin Zhong, Lingli Dong
464 [GO] 2020―Jul―24 Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia? Emine Duran, Levent Kilic, Gamze Durhan, Ahmet Çağkan Inkaya, Gulay Sain Guven, Gul Karakaya, et al. (+2)
465 [GO] 2020―Jul―22 Response to: ‘Should patients starting biologics be screened for COVID-19?’ by Cardenas-de la Garza et al Robert B M Landewé, Hendrik Schulze-Koops
466 [GO] 2020―Jul―21 COVID-19 and Behçet’s disease: clinical case series Gerard Espinosa, Olga Araujo, Sergi Amaro, Marta Bodro, Pedro Juan Moreno, Reinaldo Moreno, et al. (+2)
467 [GO] 2020―Jul―21 Comment on: ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al Samet Karahan, Ali Cetinkaya, Kaniye Aydin, Hatice Aslan Sirakaya
468 [GO] 2020―Jul―21 COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre Natasha Cleaton, Sabrina Raizada, Nick Barkham, Srinivasan Venkatachalam, Tom Sheeran, Tochukwu Adizie, et al. (+3)
469 [GO] 2020―Jul―21 Historically controlled comparison of glucocorticoids with or without tocilizumab versus supportive care only in patients with COVID-19-associated cytokine storm syndrome: results of the CHIC study Sofia Ramiro, Rémy L M Mostard, César Magro-Checa, Christel M P van Dongen, Tom Dormans, Jacqueline Buijs, et al. (+8)
470 [GO] 2020―Jul―21 Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence-radiological differences Piero Ruscitti, Federico Bruno, Onorina Berardicurti, Chiara Acanfora, Viktoriya Pavlych, Pierpaolo Palumbo, et al. (+10)
471 [GO] 2020―Jul―15 Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia Samy Hakroush, Jonas Franz, Jörg Larsen, Peter Korsten, Martin Sebastian Winkler, Björn Tampe
472 [GO] 2020―Jul―15 Response to: ‘Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India’ by Goyal et al Alexis Mathian, Zahir Amoura
473 [GO] 2020―Jul―15 Impact of COVID-19 pandemic on patients with SLE: results of a large multicentric survey from India Mohit Goyal, Pravin Patil, Himanshu Pathak, Sham Santhanam, Anshul Goel, Vishnu Sharma, et al. (+16)
474 [GO] 2020―Jul―13 COVID-19 in patients with rheumatic diseases: what is the real mortality risk? Claudia Marques, Marcelo M Pinheiro, Edgard Torres Reis Neto, Andrea Tavares Dantas, Francinne Machado Ribeiro, Ana Karla G Melo
475 [GO] 2020―Jul―10 Rheumatic disease and COVID-19 Jean W Liew, Elizabeth R Graef
476 [GO] 2020―Jul―09 Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, et al. (+2)
477 [GO] 2020―Jul―09 Emergency arising from patients' fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest? Pedro Santos-Moreno, Diana Buitrago-Garcia, Laura Villarreal, Anggie Aza, Michael Cabrera, Wilberto Rivero, Adriana Rojas-Villarraga
478 [GO] 2020―Jul―09 Response to: ‘Emergency arising from patients’ fear of taking antimalarials during these COVID-19 times: are antimalarials as unsafe for cardiovascular health as recent reports suggest?’ by Santos-Mareno et al Jean W Liew, Elizabeth R Graef, Jeffrey A Sparks, Alfred Hyoungju Kim
479 [GO] 2020―Jul―06 Serological tests confirm the low incidence of COVID-19 in chronic rheumatic inflammatory diseases treated with biological DMARD Maurizio Benucci, Arianna Damiani, Gianfranco Giannasi, Francesca Li Gobbi, Luca Quartuccio, Valentina Grossi, et al. (+2)
480 [GO] 2020―Jul―06 COVID-19 in paediatric rheumatology patients treated with b/tsDMARDs: a cross-sectional patient survey study Muserref Kasap Cuceoglu, Ezgi Deniz Batu, Yelda Bilginer, Seza Özen
481 [GO] 2020―Jul―06 Should patients starting biologics be screened for COVID-19? Jesus Alberto Cardenas-de la Garza, Rosa I Arvizu-Rivera, Dionicio Angel Galarza-Delgado
482 [GO] 2020―Jul―06 Comparative analysis of synovial inflammation after SARS-CoV-2 infection Stefano Alivernini, Antonella Cingolani, Marco Gessi, Annamaria Paglionico, Giuliana Pasciuto, Barbara Tolusso, et al. (+2)
483 [GO] 2020―Jul―06 Response to: ‘Comparative analysis of synovial inflammation after SARS-CoV-2 infection’ by Alivernini et al María-del-Carmen López-González, Vega Jovani, Esperanza Merino, Paloma Vela, Mariano Andrés
484 [GO] 2020―Jul―03 Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study Emanuel Della-Torre, Corrado Campochiaro, Giulio Cavalli, Giacomo De Luca, Angela Napolitano, Salvatore La Marca, et al. (+12)
485 [GO] 2020―Jul―02 Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey Marlene Plüß, Gamal Chehab, Peter Korsten
486 [GO] 2020―Jul―02 Response to: ‘Concerns and needs of patients with systemic lupus erythematosus regarding hydroxychloroquine supplies during the COVID-19 pandemic: results from a patient-centred survey’ by Plüß et al Alexis Mathian, Zahir Amoura
487 [GO] 2020―Jul―01 COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic Richard Oluyinka Akintayo, Akpabio Akpabio, Asgar Kalla, Dzifa Dey, Angela Migowa, Hakeem Olaosebikan, et al. (+18)
488 [GO] 2020―Jun―30 Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis Andrea Hermina Györfi, Markus Kopp, Matthias May, Marcel Vetter, Michael Uder, Andreas E Kremer, et al. (+3)
489 [GO] 2020―Jun―30 Response to: ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ by Györfi et al Milena Gianfrancesco, Kimme L Hyrich, Jinoos Yazdany, Pedro M Machado, Philip C Robinson
490 [GO] 2020―Jun―30 Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases Laura Nuño, Marta Novella Navarro, Gema Bonilla, Karen Franco-Gómez, Pilar Aguado, Diana Peiteado, et al. (+11)
491 [GO] 2020―Jun―26 Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab Hendrik Schulze-Koops, Klaus Krueger, Inka Vallbracht, Rebecca Hasseli, Alla Skapenko
492 [GO] 2020―Jun―26 Clinical course and outcome of COVID-19 in patients with rheumatic diseases: are all biological disease-modifying antirheumatic drugs alike? Response to: ‘Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab’ by Schulze-Koops et al Sara Monti, Carlomaurizio Montecucco
493 [GO] 2020―Jun―26 Case of acute arthritis following SARS-CoV-2 infection Naoto Yokogawa, Naoto Minematsu, Harutaka Katano, Tadaki Suzuki
494 [GO] 2020―Jun―25 Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors Vega Jovani, Irene Calabuig, Maria Luisa Peral-Garrido, Ernesto Tovar-Sugrañes, María-del-Carmen López-González, Pilar Bernabeu, et al. (+9)
495 [GO] 2020―Jun―25 Response to: ‘Incidence of severe COVID-19 in a Spanish cohort of 1037 patients with rheumatic diseases treated with biologics and JAK-inhibitors’ by Jovani et al Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary S Wallace
496 [GO] 2020―Jun―25 Systematic analysis of COVID-19 infection and symptoms in a systemic lupus erythematosus population: correlation with disease characteristics, hydroxychloroquine use and immunosuppressive treatments Zoé Gendebien, Christian von Frenckell, Clio Ribbens, Béatrice André, Marie Thys, Marjorie Gangolf, et al. (+3)
497 [GO] 2020―Jun―25 Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic Pedro Santos-Moreno, Josefina Chavez-Chavez, Sandra Milena Hernández-Zambrano, Diana Patricia Rivera-Triana, Ruth Alexandra Castiblanco-Montañez, Anggie Aza, et al. (+3)
498 [GO] 2020―Jun―25 Response to: ‘Experience of telemedicine use in a big cohort of patients with rheumatoid arthritis during COVID-19 pandemic’ by Santos-Moreno et al Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
499 [GO] 2020―Jun―25 Hydroxychloroquine shortages among patients with systemic lupus erythematosus during the COVID-19 pandemic: experience of the Systemic Lupus International Collaborating Clinics Arielle Mendel, Sasha Bernatsky, Anca Askanase, Sang-Cheol Bae, Ann Elaine Clarke, Nathalie Costedoat-Chalumeau, et al. (+11)
500 [GO] 2020―Jun―24 Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19 Panayiotis G Vlachoyiannopoulos, Eleni Magira, Haris Alexopoulos, Edison Jahaj, Katerina Theophilopoulou, Anastasia Kotanidou, Athanasios G Tzioufas
501 [GO] 2020―Jun―24 Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak Ho So, Cheuk-Chun Szeto, Lai-Shan Tam
502 [GO] 2020―Jun―24 Telemedicine holds many promises but needs to be developed to be accepted by patients as an alternative to a visit to the doctor. Response to: ‘Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak’ by So et al Hendrik Schulze-Koops, Christof Specker, Klaus Krueger
503 [GO] 2020―Jun―23 Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience Rita Angélica Pineda-Sic, Dionicio Angel Galarza-Delgado, Griselda Serna-Peña, Sergio A Castillo-Torres, Diana Elsa Flores-Alvarado, Jorge A Esquivel-Valerio, Iván De Jesús Hernández-Galarza
504 [GO] 2020―Jun―23 Actions required to assure continuous supply of anti-rheumatic medication during the SARS-CoV-2/COVID-19 pandemic. Response to: ‘Treatment adherence behaviours in rheumatic diseases during pandemic COVID-19: a Latin American experience’ by Pineda-Sic et al Hendrik Schulze-Koops, Klaus Krueger, Christof Specker
505 [GO] 2020―Jun―22 Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: ‘Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?’ by Xie et al Carmen Magdalena Gamboa-Alonso, Gabriel Figueroa-Parra, Dionicio Angel Galarza-Delgado
506 [GO] 2020―Jun―19 Challenges and opportunities in telerheumatology in the COVID-19 era. Response to: ‘Online management of rheumatoid arthritis during COVID-19 pandemic’ by Zhang et al Gabriel Figueroa-Parra, Carmen Magdalena Gamboa-Alonso, Dionicio Angel Galarza-Delgado
507 [GO] 2020―Jun―19 Mounting data indicate that antimalarials do not prevent mild or severe COVID-19 in rheumatic patients. Response to: ‘The role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients’ by Favalli et al Vasco C Romão, Ana Rita Cruz-Machado, João Eurico Fonseca
508 [GO] 2020―Jun―19 Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients Ennio Giulio Favalli, Orazio De Lucia, Martina Biggioggero, Nicoletta Del Papa, Roberto Caporali
509 [GO] 2020―Jun―16 Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot pot’ versus in US ‘hot pot’: similarity and difference Jun Zhao, Rongrong Pang, Jian Wu, Yanju Guo, Yang Yang, Libo Zhang, Xinyi Xia
510 [GO] 2020―Jun―16 Response to: ‘COVID-19 in patients with rheumatological diseases treated with Anti-TNF’ by Brito et al and ‘Clinical characteristics and outcomes of patients with COVID-19 and rheumatic disease in China ‘hot pot’ versus in US ‘hot pot’: similarity and difference’ by Zhao et al Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Jeffrey A Sparks, Zachary Scott Wallace
511 [GO] 2020―Jun―16 Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study Yao Huang, Zhe Chen, Yu Wang, Liang Han, Kai Qin, Wenya Huang, et al. (+8)
512 [GO] 2020―Jun―16 COVID-19 in patients with rheumatological diseases treated with anti-TNF Carlos Antunes Brito, José Gerardo Paiva, Fernando Nunes Pimentel, Rosinete Santos Guimarães, Mariana Ribeiro Moreira
513 [GO] 2020―Jun―12 Prevalence of hospital PCR-confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases Jose L Pablos, Lydia Abasolo, Jose M Alvaro-Gracia, Francisco J Blanco, Ricardo Blanco, Isabel Castrejón, et al. (+9)
514 [GO] 2020―Jun―11 Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort Luisa Costa, Marco Tasso, Nadia Scotti, Erika Mostacciuolo, Nicolò Girolimetto, Francesca Foglia, et al. (+3)
515 [GO] 2020―Jun―11 Response to: ‘Telerheumatology in COVID-19 era: a study from a psoriatic arthritis cohort’ by Costa et al Latika Gupta, Durga Prasanna Misra, Vishwesh Agarwal, Suma Balan, Vikas Agarwal
516 [GO] 2020―Jun―11 Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort Marie Pouletty, Charlotte Borocco, Naim Ouldali, Marion Caseris, Romain Basmaci, Noémie Lachaume, et al. (+22)
517 [GO] 2020―Jun―10 Biologics, spondylitis and COVID-19 James Todd Rosenbaum, Hedley Hamilton, Dongseok Choi, Michael H Weisman, John D Reveille, Kevin L Winthrop
518 [GO] 2020―Jun―08 Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak Jan Holubar, Moglie Le Quintrec, Hind Letaief, Jean Luc Faillie, Yves-Marie Pers, Christian Jorgensen
519 [GO] 2020―Jun―08 Response to: ‘Monitoring of patients with systemic lupus erythematosus during the COVID-19 outbreak’ by Holubar et al Alexis Mathian, Zahir Amoura
520 [GO] 2020―Jun―05 Response to: ‘Severe COVID-19 associated pneumonia in 3 patients with systemic sclerosis treated with rituximab’ by Avouac et al Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques Maria, et al. (+4)
521 [GO] 2020―Jun―05 Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies Carlos Sanchez-Piedra, Cesar Diaz-Torne, Javier Manero, José M Pego-Reigosa, Íñigo Rúa-Figueroa, Miguel A Gonzalez-Gay, et al. (+2)
522 [GO] 2020―Jun―05 COVID-19 infection in a patient with FMF: does colchicine have a protective effect? Senol Kobak
523 [GO] 2020―Jun―05 Telemedicine will not keep us apart in COVID-19 pandemic Simone Perniola, Stefano Alivernini, Valentina Varriano, Annamaria Paglionico, Giacomo Tanti, Pietro Rubortone, et al. (+7)
524 [GO] 2020―Jun―05 Telemedicine: a useful tool but not the holy grail. Response to: ‘Telemedicine will not keep us apart in the COVID-19 pandemic’ by Perniola et al Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
525 [GO] 2020―Jun―05 COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases Clementina López-Medina, Alejandro Escudero, Eduardo Collantes-Estevez
526 [GO] 2020―Jun―05 Candidate rheumatologic treatments for COVID-19. Response to: ‘COVID-19 infection in a patient with FMF: does colchicine have a protective effect?’ by Kobak Sara Monti, Carlomaurizio Montecucco
527 [GO] 2020―Jun―05 Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab Jérôme Avouac, Paolo Airó, Nicolas Carlier, Marco Matucci-Cerinic, Yannick Allanore
528 [GO] 2020―Jun―05 EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 Robert BM Landewé, Pedro M Machado, Féline Kroon, Hans WJ Bijlsma, Gerd R Burmester, Loreto Carmona, et al. (+13)
529 [GO] 2020―Jun―05 Response to: ‘COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases’ by Lopez-Medina et al Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
530 [GO] 2020―Jun―03 COVID-19 in rheumatology outpatient clinics: Dutch mirror image to Lombardy, Italy Sophie Benoy, Rene Traksel, Peter Verhaegh, Jasper Broen
531 [GO] 2020―May―31 Patients with systemic lupus erythematosus using hydroxychloroquine or chloroquine develop severe COVID-19 at similar frequency as patients not on antimalarials: need to explore antithrombotic benefits for COVID-19 coagulopathy. Response to: ‘Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Carbillon et al Maximilian F Konig, Milena Gianfrancesco, Jinoos Yazdany, Philip C Robinson
532 [GO] 2020―May―31 Clinical course of COVID-19 in patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine Lionel Carbillon, Amélie Benbara, Jeremy Boujenah
533 [GO] 2020―May―31 Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic George E Fragoulis, Gerasimos Evangelatos, Aikaterini Arida, Vasiliki-Kalliopi Bournia, Kalliopi Fragiadaki, Anastasios Karamanakos, et al. (+6)
534 [GO] 2020―May―31 No advice to discontinue antirheumatic therapy for non-medical reasons in light of SARS-CoV-2. Response to: ‘Treatment adherence of patients with sytemic rheumatic diseases in COVID-19 pandemic’ by Fragoulis et al Hendrik Schulze-Koops, Klaus Krueger, Christof Specker
535 [GO] 2020―May―31 Patients with lupus with COVID-19: University of Michigan experience Beth Wallace, Laraine Washer, Wendy Marder, J Michelle Kahlenberg
536 [GO] 2020―May―31 Response to: ‘Patients with lupus with COVID-19: University of Michigan experience’ by Wallace et al Alexis Mathian, Zahir Amoura
537 [GO] 2020―May―29 Case series of acute arthritis during COVID-19 admission María-del-Carmen López-González, Maria Luisa Peral-Garrido, Irene Calabuig, Ernesto Tovar-Sugrañes, Vega Jovani, Pilar Bernabeu, et al. (+8)
538 [GO] 2020―May―29 Response to: ‘Case series of acute arthritis in COVID-19 admission’ by López-González et al Elizabeth R Graef, Jean W Liew, Alfred HJ Kim, Jeffrey A Sparks
539 [GO] 2020―May―29 Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Milena Gianfrancesco, Kimme L Hyrich, Sarah Al-Adely, Loreto Carmona, Maria I Danila, Laure Gossec, et al. (+22)
540 [GO] 2020―May―29 Correspondence regarding research letter to the editor by Mathian et al, ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’ Mandana Nikpour, Benjamin Teh, Ian P Wicks, Marc Pellegrini
541 [GO] 2020―May―29 Response to: Correspondence regarding research letter to the editor by Mathian et al, ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus under long-term treatment with hydroxychloroquine’’ by Nikpour et al Alexis Mathian, Zahir Amoura
542 [GO] 2020―May―28 Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study Carlo Salvarani, Gianluigi Bajocchi, Pamela Mancuso, Elena Galli, Francesco Muratore, Luigi Boiardi, et al. (+14)
543 [GO] 2020―May―26 Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US ‘hot spot’ Kristin M D’Silva, Naomi Serling-Boyd, Rachel Wallwork, Tiffany Hsu, Xiaoqing Fu, Ellen M Gravallese, et al. (+3)
544 [GO] 2020―May―25 Are patients with systemic lupus erythematosus at increased risk for COVID-19? Ennio Giulio Favalli, Maria Gerosa, Antonella Murgo, Roberto Caporali
545 [GO] 2020―May―25 Response to: ‘Are patients with systemic lupus erythematosus at increased risk for COVID-19?’ by Favalli et al Alexis Mathian, Zahir Amoura
546 [GO] 2020―May―24 Online management of rheumatoid arthritis during COVID-19 pandemic Yang Zhang, Jian Wang, Liang Zhao, Jun Xiao, Zhanjun Shi
547 [GO] 2020―May―24 Impact of delayed diagnoses at the time of COVID-19: increased rate of preventable bilateral blindness in giant cell arteritis Sara Monti, Paolo Delvino, Elisa Bellis, Alessandra Milanesi, Fabio Brandolino, Carlomaurizio Montecucco
548 [GO] 2020―May―23 COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine Emanuele Bozzalla Cassione, Giovanni Zanframundo, Alessandro Biglia, Veronica Codullo, Carlomaurizio Montecucco, Lorenzo Cavagna
549 [GO] 2020―May―23 Response to ‘To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic’ by Parperis Francesca Romana Spinelli, Fulvia Ceccarelli, Manuela Di Franco, Fabrizio Conti
550 [GO] 2020―May―23 The conundrum of COVID-19 treatment targets: the close correlation with rheumatology. Response to: ‘Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology pracitioners from India’ by Gupta et al and ‘Antirheumatic agents in covid-19: is IL-6 the right target?’ by Capeechi et al Sara Monti, Carlomaurizio Montecucco
551 [GO] 2020―May―22 Recovery from COVID-19 in a patient with spondyloarthritis treated with TNF-alpha inhibitor etanercept Pierre-Marie Duret, Eden Sebbag, Auriane Mallick, Simon Gravier, Lionel Spielmann, Laurent Messer
552 [GO] 2020―May―22 Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China Cong Ye, Shaozhe Cai, Guifen Shen, Hanxiong Guan, Liling Zhou, Yangyang Hu, et al. (+7)
553 [GO] 2020―May―22 Antibodies against immunogenic epitopes with high sequence identity to SARS-CoV-2 in patients with autoimmune dermatomyositis Spyridon Megremis, Thomas D J Walker, Xiaotong He, William E R Ollier, Hector Chinoy, Lynne Hampson, et al. (+2)
554 [GO] 2020―May―21 Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19 Maximilian F Konig, Alfred HJ Kim, Marc H Scheetz, Elizabeth R Graef, Jean W Liew, Julia Simard, et al. (+5)
555 [GO] 2020―May―21 Response to ‘Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)?’ by Moiseev et al Francesca Romana Spinelli, Fulvia Ceccarelli, Manuela Di Franco, Fabrizio Conti
556 [GO] 2020―May―21 Non-steroidal anti-inflammatory treatment during covid-19: friend or foe? Response to: ‘Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID)’ by Giollo et al Sara Monti, Carlomaurizio Montecucco
557 [GO] 2020―May―21 Impact of COVID-19 pandemic on patients with large-vessel vasculitis in Italy: a monocentric survey Alessandro Tomelleri, Silvia Sartorelli, Corrado Campochiaro, Elena Marina Baldissera, Lorenzo Dagna
558 [GO] 2020―May―20 Rheumatic diseases in intensive care unit patients with COVID-19 Sergey Moiseev, Sergey Avdeev, Michail Brovko, Andrey Yavorovskiy, Pavel I Novikov, Karina Umbetova, et al. (+3)
559 [GO] 2020―May―20 Severe COVID-19 and related hyperferritinaemia: more than an innocent bystander? Piero Ruscitti, Onorina Berardicurti, Antonio Barile, Paola Cipriani, Yehuda Shoenfeld, Annamaria Iagnocco, Roberto Giacomelli
560 [GO] 2020―May―20 Hydroxychloroquine shortages during the COVID-19 pandemic Arielle Mendel, Sasha Bernatsky, J Carter Thorne, Diane Lacaille, Sindhu R Johnson, Évelyne Vinet
561 [GO] 2020―May―20 Response to: ‘Hydroxychloroquine shortages during the COVID-19 pandemic’ by Mendel et al Iain McInnes
562 [GO] 2020―May―20 Comorbidities and rheumatological diseases at the time of COVID-19. Response to: ‘Rheumatic diseases in intensive care unit patients with COVID-19’ by Moiseev et al Sara Monti, Carlomaurizio Montecucco
563 [GO] 2020―May―18 Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation? Gian Luca Erre, Edoardo Sean Ferraccioli, Matteo Piga, Arduino Mangoni, Giuseppe Passiu, Elisa Gremese, Gianfranco Ferraccioli
564 [GO] 2020―May―18 Response to: ‘Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?’ by Erre et al Elizabeth R Graef, Jean W Liew, Alfred HJ Kim, Jeffrey A Sparks
565 [GO] 2020―May―15 Prevalence of COVID-19 among patients with rheumatic diseases: the need to await results from large collaborative studies. Response to: ‘COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs’ by Conticini et al Sara Monti, Carlomaurizio Montecucco
566 [GO] 2020―May―15 COVID-19 pneumonia in a large cohort of patients treated with biological and targeted synthetic antirheumatic drugs Edoardo Conticini, Elena Bargagli, Marco Bardelli, Giuseppe Domenico Rana, Caterina Baldi, Paolo Cameli, et al. (+9)
567 [GO] 2020―May―15 Diagnostic and therapeutic challenges for patients with ANCA-associated vasculitides at the time of COVID-19. Response to: ‘Rituximab for granulomatosis with polyangiitis in the pandemic of COVID-19: lessons from a case with severe pneumonia’ by Guilpain et al Sara Monti, Carlomaurizio Montecucco
568 [GO] 2020―May―13 Response to: ‘Patients with lupus are not protected from COVID-19: a comment’ by Sawalha, ‘No evidence so far on the protective effect of hydroxycloroquin to prevent COVID-19: response to the Comment by Joob and Wiwanitkit’ by Romão et al and ‘SLE patients are not immune to COVID-19: importance of sending the right message across’ by Goyal Beuy Joob, Viroj Wiwanitkit
569 [GO] 2020―May―13 No evidence so far on the protective effect of hydroxychloroquine to prevent COVID-19: response to the comment by Joob and Wiwanitkit Vasco C. Romão, Ana Rita Cruz-Machado, João Eurico Fonseca
570 [GO] 2020―May―06 Targeting the inflammatory cascade with anakinra in moderate to severe COVID-19 pneumonia: case series Achille Aouba, Aurelie Baldolli, Loïk Geffray, Renaud Verdon, Emmanuel Bergot, Nicolas Martin-Silva, Aurélien Justet
571 [GO] 2020―Apr―28 Anti-inflammatory therapy may ameliorate the clinical picture of COVID-19 Haralampos M Moutsopoulos
572 [GO] 2020―Apr―24 Patients with lupus are not protected from COVID-19 Amr H Sawalha
573 [GO] 2020―Apr―23 Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: ‘Does hydroxychloroquine prevent the transmission of COVID-19?’ by Heldwein and Calado and ‘SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment’ by Joob and Wiwanitkit Sara Monti, Carlomaurizio Montecucco
574 [GO] 2020―Apr―23 SLE patients are not immune to covid-19: importance of sending the right message across Mohit Goyal
575 [GO] 2020―Apr―23 Myositis as a manifestation of SARS-CoV-2 Maxime Beydon, Kevin Chevalier, Omar Al Tabaa, Sabrina Hamroun, Anne-Sophie Delettre, Marion Thomas, et al. (+3)
576 [GO] 2020―Apr―22 Coronavirus disease 19 (Covid-19) and non-steroidal anti-inflammatory drugs (NSAID) Alessandro Giollo, Giovanni Adami, Davide Gatti, Luca Idolazzi, Maurizio Rossini
577 [GO] 2020―Apr―22 What is the true incidence of COVID-19 in patients with rheumatic diseases? Ennio Giulio Favalli, Francesca Ingegnoli, Rolando Cimaz, Roberto Caporali
578 [GO] 2020―Apr―22 To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (COVID-19) pandemic Konstantinos Parperis
579 [GO] 2020―Apr―21 Is there a future for hydroxychloroquine/chloroquine in prevention of SARS-CoV-2 infection (COVID-19)? Sergey Moiseev, Sergey Avdeev, Michail Brovko, Pavel Novikov, Victor Fomin
580 [GO] 2020―Apr―21 Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality? Wenhui Xie, Yu Wang, Zhuoli Zhang
581 [GO] 2020―Apr―20 Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia Philippe Guilpain, Clément Le Bihan, Vincent Foulongne, Patrice Taourel, Nathalie Pansu, Alexandre Thibault Jacques MARIA, et al. (+4)
582 [GO] 2020―Apr―16 COVID-19 and rheumatology: first steps towards a different future? Iain B McInnes
583 [GO] 2020―Apr―16 Management of rheumatic diseases in the time of covid-19 pandemic: perspectives of rheumatology practitioners from India Latika Gupta, Durga Prasanna Misra, Vishwesh Agarwal, Suma Balan, Vikas Agarwal
584 [GO] 2020―Apr―16 Antirheumatic agents in covid-19: is IL-6 the right target? Pier Leopoldo Capecchi, Pietro Enea Lazzerini, Luca Volterrani, Maria Antonietta Mazzei, Barbara Rossetti, Giacomo Zanelli, et al. (+7)
585 [GO] 2020―Apr―15 Role of immunosuppressive therapy in rheumatic diseases concurrent with covid-19 Chenyang Lu, Shasha Li, Yi Liu
586 [GO] 2020―Apr―15 Festina lente: hydroxychloroquine, covid-19 and the role of the rheumatologist Elizabeth R Graef, Jean W Liew, Michael S Putman, Julia F Simard, Emily Sirotich, Francis Berenbaum, et al. (+13)
587 [GO] 2020―Apr―15 SLE, hydroxychloroquine and no SLE patients with covid-19: a comment Beuy Joob, Viroj Wiwanitkit
588 [GO] 2020―Apr―15 Does hydroxychloroquine prevent the transmission of covid-19? Flavio L Heldwein, Adriano Calado
589 [GO] 2020―Apr―03 COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD Carina Mihai, Rucsandra Dobrota, Maria Schröder, Alexandru Garaiman, Suzana Jordan, Mike Oliver Becker, et al. (+2)
590 [GO] 2020―Apr―03 Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Sara Monti, Silvia Balduzzi, Paolo Delvino, Elisa Bellis, Verdiana Serena Quadrelli, Carlomaurizio Montecucco
591 [GO] 2020―Apr―03 To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic Francesca Romana Spinelli, Fulvia Ceccarelli, Manuela Di Franco, Fabrizio Conti
592 [GO] 2020―Mar―23 Are my patients with rheumatic diseases at higher risk of COVID-19? Gabriel Figueroa-Parra, Gloria Mayela Aguirre-Garcia, Carmen Magdalena Gamboa-Alonso, Adrian Camacho-Ortiz, Dionicio Angel Galarza-Delgado
 [1] 

592 Results       Page 1



[de][en]

Last change 2022―Feb―03 17:06:14 UTC

© Daten-Quadrat 2022       Done in 0.259 sec